



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 313 578 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
28.08.1996 Bulletin 1996/35

(51) Int Cl. 6: **C07K 14/51, C12N 15/12,
A61K 38/18**

(21) Application number: **87905023.5**

(86) International application number:
PCT/US87/01537

(22) Date of filing: **30.06.1987**

(87) International publication number:
WO 88/00205 (14.01.1988 Gazette 1988/02)

(54) NOVEL OSTEOINDUCTIVE COMPOSITIONS

OSTEOINDUKTIVE MITTEL

NOUVELLES COMPOSITIONS OSTEOINDUCTIVES

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(74) Representative: **VOSSIUS & PARTNER**
Postfach 86 07 67
81634 München (DE)

(30) Priority: **01.07.1986 US 880776**
17.12.1986 US 943332
20.03.1987 US 28285
26.03.1987 US 31346

(56) References cited:
EP-A- 0 121 976 EP-A- 0 128 041
EP-A- 0 148 155 EP-A- 0 212 474
WO-A-85/04173 US-A- 4 455 256
US-A- 4 563 350 US-A- 4 619 989

(43) Date of publication of application:
03.05.1989 Bulletin 1989/18

- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 81, January 1984, Washington, DC (US); URIST, pp. 371-375
- SCIENCE, vol. 220, 13 May 1983, Washington, DC (US); URIST, pp. 680-686
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 80, November 1983, Washington, DC (US); SAMPATH et al., pp. 6591-6595
- PROCEEDINGS OF THE NATL. ACADEMY OF SCIENCES USA, vol. 78, November 1981, Washington, DC (US); SUGGS et al., pp. 6613-6617

(60) Divisional application: **95111771.2**

(73) Proprietor: **GENETICS INSTITUTE, INC.**
Cambridge, Massachusetts 02140 (US)

(72) Inventors:

- WANG, Elizabeth, A.
Carlisle, MA 01741 (US)
- WOZNEY, John, M.
Hudson, MA 01749 (US)
- ROSEN, Vicki, A.
Boston, MA 02116 (US)

EP 0 313 578 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

The present invention relates to novel proteins, processes for obtaining them and genes encoding them. These proteins are capable of inducing cartilage and bone formation.

5

Background

Bone is a highly specialized tissue characterized by an extensive matrix structure formed of fibrous bundles of the protein collagen, and proteoglycans, noncollagenous proteins, lipids and acidic proteins. The processes of bone formation and renewal/repair of bone tissue, which occur continuously throughout life, are performed by specialized cells. Normal embryonic long bone development is preceded by formation of a cartilage model. Bone growth is presumably mediated by "osteoblasts" (bone-forming cells), while remodeling of bone is apparently accomplished by the joint activities of bone-resorbing cells, called "osteoclasts" and osteoblasts. A variety of osteogenic, cartilage-inducing and bone inducing factors have been described. See, e.g. European patent applications 148,155 and 169,016 for discussions thereof.

Brief Description of the Invention

The present invention provides novel proteins in purified form and genes encoding them. Specifically, two of the novel proteins are designated BMP-2 Class I (or BMP-2), and BMP-2 Class II (or BMP-4) wherein BMP is bone morphogenic protein. These proteins are characterized by peptide sequences the same as or substantially homologous to amino acid sequences illustrated in Tables II, III and IV below. They are capable of inducing bone formation at a predetermined site. These bone inductive factors are further characterized by biochemical and biological characteristics including activity at a concentration of 10 to 1000ng/gram of bone in an *in vivo* rat bone formation assay described below. Proteins of this invention may be encoded by the DNA sequences depicted in the Tables or by sequences capable of hybridizing thereto and coding for polypeptides with bone growth factor biological properties or other variously modified sequences demonstrating such properties.

One of the proteins of the invention is designated BMP-2 Class I (or BMP-2). It is characterized by at least a portion of a peptide sequence the same or substantially the same as that of amino acid #1 through amino acid #396 of Table III which represents the cDNA hBMP-2 Class I. This peptide sequence is encoded by the same or substantially the same DNA sequence, as depicted in nucleotide #356 through nucleotide #1543 of Table III. The human peptide sequence identified in Table III is 396 amino acids in length. hBMP-2 or related bone inductive proteins may also be characterized by at least a portion of this peptide sequence. hBMP-2 Class I is further characterized by the ability to induce bone formation.

The homologous bovine bone inductive protein of the invention designated bBMP-2 Class I (or bBMP-2), has a DNA sequence identified in Table II below which represents the genomic sequence. This bovine DNA sequence has a prospective 129 amino acid coding sequence followed by approximately 205 nucleotides (a presumptive 3' non-coding sequence). bBMP-2, Class I is further characterized by the ability to induce bone formation. A further bone inductive protein composition of the invention is designated BMP-2 Class II or BMP-4. The human protein hBMP-2 Class II (or hBMP-4) is characterized by at least a portion of the same or substantially the same peptide sequence between amino acid #1 through amino acid #408 of Table IV, which represents the cDNA of hBMP-2 Class II. This peptide sequence is encoded by at least a portion of the same or substantially the same DNA sequence as depicted in nucleotide #403 through nucleotide #1626 of Table IV. This factor is further characterized by the ability to induce bone formation.

Another aspect of the invention provides pharmaceutical compositions containing a therapeutically effective amount of one or more bone growth factor polypeptides according to the invention in a pharmaceutically acceptable vehicle. These compositions may further include other therapeutically useful agents. They may also include an appropriate matrix for delivering the proteins to the site of the bone defect and for providing a structure for bone growth. These compositions may be employed in methods for treating a number of bone defects and periodontal disease. These methods, according to the invention, entail administering to a patient needing such bone formation an effective amount of at least one of the novel proteins BMP-2 Class I and BMP-2 Class-II as described herein.

Still a further aspect of the invention are DNA sequences coding on expression for a human or bovine polypeptide having the ability to induce bone formation. Such sequences include the sequence of nucleotides in a 5' to 3' direction illustrated in Tables II, III and IV. Alternatively, a DNA sequence which hybridizes under stringent conditions with the DNA sequences of Tables II, III and IV or a DNA sequence which hybridizes under non-stringent conditions with the illustrated DNA sequences and which codes on expression for a protein having at least one bone growth factor biological property are included in the present invention. Finally, allelic or other variations of the sequences of Tables II, III and IV, whether such nucleotide changes result in changes in the peptide sequence or not, are also included in the present

invention.

Still a further aspect of the invention is a vector containing a DNA sequence as described above in operative association with an expression control sequence. Such vector may be employed in a novel process for producing a bone growth factor polypeptide in which a cell line transformed with a DNA sequence encoding expression of a bone growth factor polypeptide in operative association with an expression control sequence therefor, is cultured. This claimed process may employ a number of known cells as host cells for expression of the polypeptide. Presently preferred cell lines are mammalian cell lines and bacterial cells.

Other aspects and advantages of the present invention will be apparent upon consideration of the following detailed description and preferred embodiments thereof.

10

Detailed Description of the Invention

The proteins of the present invention are characterized by amino acid sequences or portions thereof the same as or substantially homologous to the sequences shown in Tables II, III and IV. These proteins are also characterized by 15 the ability to induce bone formation.

The bone growth factors provided herein also include factors encoded by the sequences similar to those of Tables II, III and IV, but into which modifications are naturally provided (e.g. allelic variations in the nucleotide sequence which may result in amino acid changes in the polypeptide) or deliberately engineered. For example, synthetic polypeptides 20 may wholly or partially duplicate continuous sequences of the amino acid residues of Tables II, III and IV. These sequences, by virtue of sharing primary, secondary, or tertiary structural and conformational characteristics with bone growth factor polypeptides of Tables II, III and IV may possess bone growth factor biological properties in common therewith. Thus, they may be employed as biologically active substitutes for naturally-occurring bone growth factor polypeptides in therapeutic processes.

Other specific mutations of the sequences of the bone growth factors described herein involve modifications of 25 one or both of the glycosylation sites. The absence of glycosylation or only partial glycosylation results from amino acid substitution or deletion at one or both of the asparagine-linked glycosylation recognition sites present in the sequences of the bone growth factors shown in Tables II, III and IV. The asparagine-linked glycosylation recognition sites comprise tripeptide sequences which are specifically recognized by appropriate cellular glycosylation enzymes. These 30 tripeptide sequences are either asparagine-X-threonine or asparagine-X-serine, where X is usually any amino acid. A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence.

The present invention also encompasses the novel DNA sequences, free of association with DNA sequences 35 encoding other proteinaceous materials, and coding on expression for bone growth factors. These DNA sequences include those depicted in Tables II, III and IV in a 5' to 3' direction and those sequences which hybridize under stringent hybridization conditions [see, T. Maniatis et al, Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory (1982), pages 387 to 389] to the DNA sequences of Tables II, III and IV.

DNA sequences which hybridize to the sequences of Tables II, III and IV under relaxed hybridization conditions 40 and which code on expression for bone growth factors having bone growth factor biological properties also encode bone growth factors of the invention. For example, a DNA sequence which shares regions of significant homology, e. g., sites of glycosylation or disulfide linkages, with the sequences of Tables II, III and IV and encodes a bone growth factor having one or more bone growth factor biological properties clearly encodes a member of this novel family of growth factors, even if such a DNA sequence would not stringently hybridize to the sequence of Tables II, III and IV.

Similarly, DNA sequences which code for bone growth factor polypeptides coded for by the sequences of Tables 45 II, III and IV, but which differ in codon sequence due to the degeneracies of the genetic code or allelic variations (naturally-occurring base changes in the species population which may or may not result in an amino acid change) also encode the novel growth factors described herein. Variations in the DNA sequences of Tables II, III and IV which are caused by point mutations or by induced modifications to enhance the activity, half-life or production of the polypeptides encoded thereby are also encompassed in the invention.

Another aspect of the present invention provides a novel method for producing the novel osteoinductive factors. 50 The method of the present invention involves culturing a suitable cell or cell line, which has been transformed with a DNA sequence coding on expression for a novel bone growth factor polypeptide of the invention, under the control of known regulatory sequences. Suitable cells or cell lines may be mammalian cells, such as Chinese hamster ovary (CHO) cells. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 293: 620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol., 5(7):1750-1759 (1985) or Howley et al, U.S. Patent 4,419,446. Another suitable mammalian cell line, which is described in the accompanying examples, is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

Bacterial cells are suitable hosts. For example, the various strains of *E. coli* (e.g., HB101, MC1061) are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Pseudomonas*, other bacilli and the like may also be employed in this method.

Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. Additionally, where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g. Miller et al, *Genetic Engineering*, 8:277-298 (Plenum Press 1986) and references cited therein.

Another aspect of the present invention provides vectors for use in the method of expression of these novel osteoinductive polypeptides. Preferably the vectors contain the full novel DNA sequences described above which code for the novel factors of the invention. Additionally the vectors also contain appropriate expression control sequences permitting expression of the bone inductive protein sequences. Alternatively, vectors incorporating modified sequences as described above are also embodiments of the present invention and useful in the production of the bone inductive proteins. The vectors may be employed in the method of transforming cell lines and contain selected regulatory sequences in operative association with the DNA coding sequences of the invention which are capable of directing the replication and expression thereof in selected host cells. Useful regulatory sequences for such vectors are known to one of skill in the art and may be selected depending upon the selected host cells. Such selection is routine and does not form part of the present invention.

A protein of the present invention, which induces bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures. An osteogenic preparation employing one or more of the proteins of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery. An osteogenic factor of the invention may be valuable in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. Of course, the proteins of the invention may have other therapeutic uses.

A further aspect of the invention is a therapeutic method and composition for repairing fractures and other conditions related to bone defects or periodontal diseases. Such a composition comprises a therapeutically effective amount of at least one of the bone inductive factor proteins of the invention. The bone inductive factors according to the present invention may be present in a therapeutic composition in admixture with a pharmaceutically acceptable vehicle or matrix. Further therapeutic methods and compositions of the invention comprise a therapeutic amount of a bone inductive factor of the invention with a therapeutic amount of at least one of the other bone inductive factors of the invention. Additionally, the proteins according to the present invention or a combination of the proteins of the present invention may be co-administered with one or more different osteoinductive factors with which they may interact. Further, the bone inductive proteins may be combined with other agents beneficial to the treatment of the bone defect in question. Such agents include, but are not limited to various growth factors. The preparation of such physiologically acceptable protein compositions, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

In particular, BMP-2 Class I may be used individually in a pharmaceutical composition. BMP-2 Class I may also be used in combination with one or more of the other proteins of the invention. BMP-2 Class I may be combined with BMP-2 Class II. It may also be combined with BMP-3. Further BMP-2 Class I may be combined with BMP-2 Class II and BMP-3.

BMP-2 Class II may be used individually in pharmaceutical composition. In addition, it may be used in combination with other proteins as identified above. Further it may be used in combination with BMP-3.

The therapeutic method includes locally administering the composition as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone damage. Preferably, the bone growth inductive factor composition would include a matrix capable of delivering the bone inductive factor to the site of bone damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of other materials presently in use for other implanted medical applications.

The choice of material is based on, for example, biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. Similarly, the application of the osteoinductive factors will define the appropriate formulation. Potential matrices for the osteoinductive factors may be biodegradable and chemically defined, such as, but not limited to calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyanhydrides; biodegradable and biologically well defined, such as bone or dermal collagen, other pure proteins or extracellular matrix components; nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics; or combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics might also be altered in composition, such as in calcium-aluminate-phos-

phate and processing to alter for example, pore size, particle size, particle shape, and biodegradability.

The dosage regimen will be determined by the attending physician considering various factors which modify the action of such a growth factor, e.g. amount of bone weight desired to be formed, the site of bone damage, the condition of the damaged bone, the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and the composition of BMP's. The addition of other known growth factors, such as IGF 1 (insulin like growth factor 1), to the final composition, may also effect the dosage. Generally, the dosage regimen should be in the range of approximately 10 to 10^6 nanograms of protein per gram of bone weight desired. Progress can be monitored by periodic assessment of bone growth and/or repair, e.g. x-rays. Such therapeutic compositions are also presently valuable for veterinary applications due to the lack of species specificity in bone inductive factors. Particularly domestic animals and thoroughbred horses in addition to humans are desired patients for such treatment with the bone inductive factors of the present invention.

The following examples illustrate practice of the present invention in recovering and characterizing the bovine proteins and employing them to recover the human proteins, obtaining the human proteins and in expressing the proteins via recombinant techniques.

EXAMPLE I

Isolation of Bovine Bone Inductive Factor

Ground bovine bone powder (20-120 mesh, Helitrex) is prepared according to the procedures of M. R. Urist et al., Proc. Natl Acad. Sci USA, 70:3511 (1973) with elimination of some extraction steps as identified below. Ten kgs of the ground powder is demineralized in successive changes of 0.6N HCl at 4°C over a 48 hour period with vigorous stirring. The resulting suspension is extracted for 16 hours at 4°C with 50 liters of 2M CaCl₂ and 10mM ethylenediaminetetraacetic acid [EDTA], and followed by extraction for 4 hours in 50 liters of 0.5M EDTA. The residue is washed three times with distilled water before its resuspension in 20 liters of 4M guanidine hydrochloride [GuCl], 20mM Tris (pH 7.4), 1 mM N-ethylmaleimide, 1mM iodoacetamide, 1mM phenylmethylsulfonyl fluoride as described in Clin. Orthop. Rel. Res., 171: 213 (1982). After 16 to 20 hours the supernatant is removed and replaced with another 10 liters of GuCl buffer. The residue is extracted for another 24 hours.

The crude GuCl extracts are combined, concentrated approximately 20 times on a Pellicon apparatus with a 10,000 molecular weight cut-off membrane, and then dialyzed in 50mM Tris, 0.1M NaCl, 6M urea (pH7.2), the starting buffer for the first column. After extensive dialysis the protein is loaded on a 4 liter DEAE cellulose column and the unbound fractions are collected.

The unbound fractions are concentrated and dialyzed against 50mM NaAc, 50mM NaCl (pH 4.6) in 6M urea. The unbound fractions are applied to a carboxymethyl cellulose column. Protein not bound to the column is removed by extensive washing with starting buffer, and the bone inductive factor containing material desorbed from the column by 50mM NaAc, 0.25mM NaCl, 6M urea (pH 4.6). The protein from this step elution is concentrated 20- to 40-fold, then diluted 5 times with 80mM KPO₄, 6M urea (pH6.0). The pH of the solution is adjusted to 6.0 with 500mM K₂HPO₄. The sample is applied to an hydroxylapatite column (LKB) equilibrated in 80mM KPO₄, 6M urea (pH6.0) and all unbound protein is removed by washing the column with the same buffer. Bone inductive factor activity is eluted with 100mM KPO₄ (pH7.4) and 6M urea.

The protein is concentrated approximately 10 times, and solid NaCl added to a final concentration of 0.15M. This material is applied to a heparin - Sepharose column equilibrated in 50mM KPO₄, 150mM NaCl, 6M urea (pH7.4). After extensive washing of the column with starting buffer, a protein with bone inductive factor activity is eluted by 50mM KPO₄, 700mM NaCl, 6M urea (pH7.4). This fraction is concentrated to a minimum volume, and 0.4ml aliquots are applied to Superose 6 and Superose 12 columns connected in series, equilibrated with 4M GuCl, 20mM Tris (pH7.2) and the columns developed at a flow rate of 0.25ml/min. The protein demonstrating bone inductive factor activity has a relative migration corresponding to approximately 30,000 dalton protein.

The above fractions are pooled, dialyzed against 50mM NaAc, 6M urea (pH4.6), and applied to a Pharmacia MonoS HR column. The column is developed with a gradient to 1.0M NaCl, 50mM NaAc, 6M urea (pH4.6). Active fractions are pooled and brought to pH3.0 with 10% trifluoroacetic acid (TFA). The material is applied to a 0.46 x 25cm Vydac C4 column in 0.1% TFA and the column developed with a gradient to 90% acetonitrile, 0.1% TFA (31.5% acetonitrile, 0.1% TFA to 49.5% acetonitrile, 0.1% TFA in 60 minutes at 1ml per minute). Active material is eluted at approximately 40-44% acetonitrile. Aliquots of the appropriate fractions are iodinated by one of the following methods: P. J. McConahey et al, Int. Arch. Allergy, 29:185-189 (1966); A. E. Bolton et al, Biochem J., 133:529 (1973); and D. F. Bowen-Pope, J. Biol. Chem., 237:5161 (1982). The iodinated proteins present in these fractions are analyzed by SDS gel electrophoresis and urea Triton X 100 isoelectric focusing. At this stage, the bone inductive factor is estimated to be approximately 10-50% pure.

EXAMPLE II

Characterization of Bovine Bone Inductive Factor

5 A. Molecular Weight

Approximately 20ug protein from Example I is lyophilized and redissolved in 1X SDS sample buffer. After 15 minutes of heating at 37°C, the sample is applied to a 15% SDS polyacrylamide gel and then electrophoresed with cooling. The molecular weight is determined relative to prestained molecular weight standards (Bethesda Research Labs).
 10 Immediately after completion, the gel lane containing bone inductive factor is sliced into 0.3cm pieces. Each piece is mashed and 1.4ml of 0.1% SDS is added. The samples are shaken gently overnight at room temperature to elute the protein. Each gel slice is desalted to prevent interference in the biological assay. The supernatant from each sample is acidified to pH 3.0 with 10% TFA, filtered through a 0.45 micron membrane and loaded on a 0.46cm x 5cm C4 Vydac column developed with a gradient of 0.1% TFA to 0.1% TFA, 90% CH₃CN. The appropriate bone inductive factor -
 15 containing fractions are pooled and reconstituted with 20mg rat matrix. In this gel system, the majority of bone inductive factor fractions have the mobility of a protein having a molecular weight of approximately 28,000 - 30,000 daltons.

B. Isoelectric Focusing

20 The isoelectric point of bone inductive factor activity is determined in a denaturing isoelectric focusing system. The Triton X100 urea gel system (Hoeffer Scientific) is modified as follows: 1) 40% of the ampholytes used are Servalyte 3/10; 60% are Servalyte 7-9. 2) The catholyte used is 40mM NaOH. Approximately 20ug of protein from Example I is lyophilized, dissolved in sample buffer and applied to the isoelectrofocusing gel. The gel is run at 20 watts, 10°C for approximately 3 hours. At completion the lane containing bone inductive factor is sliced into 0.5 cm slices. Each piece
 25 is mashed in 1.0ml 6M urea, 5mM Tris (pH 7.8) and the samples agitated at room temperature. The samples are acidified, filtered, desalted and assayed as described above. The major portion of activity as determined in the assay described in Example III migrates in a manner consistent with a pl of 8.8 - 9.2.

C. Subunit Characterization

30 The subunit composition of bone inductive factor is also determined. Pure bone inductive factor is isolated from a preparative 15% SDS gel as described above. A portion of the sample is then reduced with 5mM DTT in sample buffer and re-electrophoresed on a 15% SDS gel. The approximately 30kd protein yields two major bands at approximately 20kd and 18kd, as well as a minor band at 30kd. The broadness of the two bands indicates heterogeneity caused most probably by glycosylation, other post translational modification, proteolytic degradation or carbamylolation.
 35

EXAMPLE III

Biological Activity of Bone Inductive Factor

40 A rat bone formation assay according to the general procedure of Sampath and Reddi, Proc. Natl. Acad. Sci. U.S.A., 80:6591-6595 (1983) is used to evaluate the osteogenic activity of the bovine bone inductive factor of the present invention obtained in Example I. This assay can also be used to evaluate bone inductive factors of other species. The ethanol precipitation step is replaced by dialyzing the fraction to be assayed against water. The solution or suspension is then redissolved in a volatile solvent, e.g. 0.1 - 0.2 % TFA, and the resulting solution added to 20mg of rat matrix. This material is frozen and lyophilized and the resulting powder enclosed in #5 gelatin capsules. The capsules are implanted subcutaneously in the abdominal thoracic area of 21 - 49 day old male long Evans rats. The implants are removed after 7 - 14 days. Half of each implant is used for alkaline phosphatase analysis [See, A. H. Reddi et al., Proc. Natl. Acad. Sci., 69:1601 (1972)] and half is fixed and processed for histological analysis. Routinely, 1µm glycolmethacrylate sections are stained with Von Kossa and acid fuchsin to detect new bone mineral. Alkaline phosphatase, an enzyme produced by chondroblasts and osteoblasts in the process of matrix formation, is also measured. New cartilage and bone formation often correlates with alkaline phosphatase levels. Table I below illustrates the dose response of the rat matrix samples including a control not treated with bone inductive factor.

TABLE 1

	Protein* Implanted µg	Cartilage	Alk. Phos.u/l
5	7.5	2	Not done
	2.5	3	445.7
	0.83	3	77.4
	0.28	0	32.5
10	0.00	0	31.0

*At this stage the bone inductive factor is approximately 10-15% pure.

10

The bone or cartilage formed is physically confined to the space occupied by the matrix. Samples are also analyzed by SDS gel electrophoresis and isoelectric focusing as described above, followed by autoradiography. Analysis reveals a correlation of activity with protein bands at 28 - 30kd and a pl 9.0. An extinction coefficient of 1 OD/mg-cm is used as an estimate for protein and approximating the purity of bone inductive factor in a particular fraction. In the in vivo rat bone formation assays on dilutions as described above, the protein is active in vivo at 10 to 200ng protein/gram bone to probably greater than 1µg protein/gram bone.

15

EXAMPLE IV

20

Bovine Bone Inductive Factor Protein Composition

The protein composition of Example IIA of molecular weight 28 - 30kd is reduced as described in Example IIC and digested with trypsin. Eight tryptic fragments are isolated by standard procedures having the following amino acid sequences:

25

Fragment 1: A A F L G D I A L D E E D L G

Fragment 2: A F Q V Q Q A A D L

30

Fragment 3: N Y Q D M V V E G

Fragment 4: S T P A Q D V S R

Fragment 5: N Q E A L R

Fragment 6: L S E P D P S H T L E E

35

Fragment 7: F D A Y Y

Fragment 8: L K P S N ? A T I Q S I V E

A less highly purified preparation of protein from bovine bone is prepared according to a purification scheme similar to that described in Example I. The purification basically varies from that previously described by omission of the DE-52 column, the CM cellulose column and the mono s column, as well as a reversal in the order of the hydroxylapatite and heparin sepharose columns. Briefly, the concentrated crude 4 M extract is brought to 85% final concentration of ethanol at 4 degrees. The mixture is then centrifuged, and the precipitate redissolved in 50 mM Tris, 0.15 M NaCl, 6.0 M urea. This material is then fractionated on Heparin Sepharose as described. The Heparin bound material is fractionated on hydroxyapatite as described. The active fractions are pooled, concentrated, and fractionated on a high resolution gel filtration (TSK 30000 in 6 M guanidinium chloride, 50 mM Tris, pH 7.2). The active fractions are pooled, dialyzed against 0.1% TFA, and then fractionated on a C4 Vydac reverse phase column as described. The preparation is reduced and electrophoresed on an acrylamide gel. The protein corresponding to the 18K band is eluted and digested with trypsin. Tryptic fragments are isolated having the following amino acid sequences:

40

Fragment 9: S L K P S N H A T I Q S ? V

Fragment 10: S F D A Y Y C S ? A

Fragment 11: V Y P N M T V E S C A

45

Fragment 12: V D F A D I ? W

Tryptic Fragments 7 and 8 are noted to be substantially the same as Fragments 10 and 9, respectively.

A. bBMF-2

Two probes consisting of pools of oligonucleotides are designed on the basis of the amino acid sequence of Fragment 3 and synthesized on an automated DNA synthesizer as described above.

5

Probe #1: A C N A C C A T [A/G] T C [T/C] T G [A/G] A T

Probe #2: C A [A/G] G A [T/C] A T G G T N G T N G A

These probes are radioactively labeled and employed to screen the bovine genomic library constructed as follows:
 10 Bovine liver DNA is partially digested with the restriction endonuclease enzyme Sau 3A and sedimented through a sucrose gradient. Size fractionated DNA in the range of 15-30kb is then ligated to the lambda J1 BamH1 arms vector [Frischauf et al, *J. Mol. Biol.*, 170:827-842 (1983) Mullins et al., *Nature* 308: 856-858 (1984)]. The library is plated at 8000 recombinants per plate. Duplicate nitrocellulose replicas of the plaques are made and amplified according to a modification of the procedure of Woo et al, *Proc. Natl. Acad. Sci. USA*, 75:3688-91 (1978).

15 The radioactively labelled 17-mer Probe #1 is hybridized to the set of filters according to the following method:

The probe is kinased and hybridized to the other set of filters in 3M tetramethylammonium chloride (TMAC), 0.1M sodium phosphate pH6.5, 1mM EDTA, 5X Denhardt's, 0.6% SDS, 100ug/ml salmon sperm DNA at 48 degrees C, and washed in 3M TMAC, 50mM Tris pH8.0 at 50 degrees C. These conditions minimize the detection of mismatches to the probe pool [see, Wood et al, *Proc. Natl. Acad. Sci. U.S.A.*, 82:1585-1588 (1985)]. 400,000 recombinants are
 20 screened by this procedure. One duplicate positive is plaque purified and the DNA is isolated from a plate lysate of the recombinant bacteriophage designated lambda bP-21. Bacteriophage bP-21 was deposited with the ATCC under accession number ATCC 40310 on March 6, 1987. The bP-21 clone encodes the bovine growth factor designated bBMP-2.

25 The oligonucleotide hybridizing region of this bBMP-2 clone is localized to an approximately 1.2 kb Sac I restriction fragment which is subcloned into M13 and sequenced by standard techniques. The partial DNA sequence and derived amino acid sequence of this Sac I fragment and the contiguous Hind III-Sac I restriction fragment of bP-21 are shown below in Table II. The bBMP-2 peptide sequence from this clone is 129 amino acids in length and is encoded by the DNA sequence from nucleotide #1 through nucleotide #387. The amino acid sequence corresponding to the tryptic fragment isolated from the bovine bone 28 to 30kd material is underlined in Table II. The underlined portion of the sequence corresponds to tryptic Fragment 3 above from which the oligonucleotide probes for bBMP-2 are designed.
 30 The predicted amino acid sequence indicates that tryptic Fragment 3 is preceded by a basic residue (K) as expected considering the specificity of trypsin. The arginine residue encoded by the CGT triplet is presumed to be the carboxy-terminus of the protein based on the presence of a stop codon (TAG) adjacent to it.

35

40

45

50

55

TABLE II

	(1)	15	30	45
5	GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG			
	G H D G K G H P L H R R E K R			
	60	75	90	
	CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG			
	Q A K H K Q R K R L K S S C K			
10	105	120	135	
	AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC			
	R H P L Y V D F S D V G W N D			
15	150	165	180	
	TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG			
	W I V A P P G Y H A F Y C H G			
	195	210	225	
	GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT			
	E C P F P L A D H L N S T N H			
20	240	255	270	
	GCC ATT CTC CAA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC			
	A I V Q T L V N S V N S K I P			
25	385	300	315	
	AAG GCA TGC TGT GTC CCA ACA GAG CTC AGC GCC ATC TCC ATG CTG			
	K A C C V P T E L S A I S M L			
	330	345	360	
	TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC			
	Y L D E N E K V V L K N Y O D			
30	375	(129)	397	407
	ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAAAATA			
	M V V E G C G C R			
	417	427	437	447
	TAAATATATA TATATATATA TTAGAAAAAC AGCAAAAAAA TCAAGTTGAC			
35	467	477	487	497
	ACTTTAATAT TTCCCAATGA AGACTTTATT TATGGAATGG AATGGAGAAA			
	517	527	537	547
	AAGAAAAACA CAGCTATTTT GAAAACATA TTTATATCTA CCGAAAAGAA			
40	567	577	587	
	GTGGGAAAAA CAAATATTTT AATCAGAGAA TTATT			

EXAMPLE V

45

Human Bone Inductive FactorsA. hBMP-2: Class I and II

50 The HindIII-SacI bovine genomic bBMP-2 fragment described in Example IV A. is subcloned into an M13 vector. A 32 P-labeled single-stranded DNA probe is made from a template preparation of this subclone. This probe is used to screen polyadenylated RNAs from various cell and tissue sources.

55 Poladenylated RNAs from various cell and tissue sources are electrophoresed on formaldehyde-agarose gels and transferred to nitrocellulose by the method of Toole et al., *supra*. The probe is then hybridized to the nitrocellulose blot in 50% formamide, 5 X SSC, 0.1% SDS, 40 mM sodium phosphate pH6.5, 100 μ g/ml denatured salmon sperm DNA, and 5 mM vanadyl ribonucleosides at 42° C overnight and washed at 65° C in 0.2 X SSC, 0.1% SDS. Following autoradiography, a hybridizing band corresponding to an mRNA species of approximately 3.8 kb is detected in the lane containing RNA from the human cell line U-2 OS. The HindIII-SacI fragment is labeled with 32 P by nick translation and

used to screen the nitrocellulose filter replicas of a U-2 OS cDNA library by hybridization in standard hybridization buffer at 65° overnight followed by washing in 1 X SSC, 0.1% SDS at 65°.

This library was constructed by synthesizing cDNA from U-2 OS polyadenylated RNA and cloning into lambda gt10 by established techniques (Toole et al., *supra*). Twelve duplicate positive clones are picked and replated for secondaries. Duplicate nitrocellulose replicas are made of the secondary plates and both sets hybridized to the bovine genomic probe as the primary screening was performed. One set of filters is then washed in 1 X SSC, 0.1% SDS; the other in 0.1 X SSC, 0.1% SDS at 65°.

Two classes of hBMP-2 cDNA clones are evident based on strong (4 recombinants) or weak (7 recombinants) hybridization signals under the more stringent washing conditions (0.1 X SSC, 0.1% SDS). All 11 recombinant bacteriophages are plaque purified, small scale DNA preparations made from plate lysates of each, and the inserts subcloned into pSP65 and into M13 for sequence analysis. Sequence analysis of the strongly hybridizing clones designated hBHP-2 Class I (also known as BMP-2) indicates that they have extensive sequence homology with the sequence given in Table II. These clones are therefore cDNA encoding the human equivalent of the protein encoded by the bBMP-2 gene whose partial sequence is given in Table II. Sequence analysis of the weakly hybridizing recombinants designated hBMP-2 Class II (also known as BMP-4) indicates that they are also quite homologous with the sequence given in Table II at the 3' end of their coding regions, but less so in the more 5' regions. Thus they encode a human protein of similar, though not identical, structure to that above.

Full length hBMP-2 Class I cDNA clones are obtained in the following manner. The 1.5 kb insert of one of the Class II subclones (II-10-1) is isolated and radioactively labeled by nick-translation. One set of the nitrocellulose replicas of the U-2 OS cDNA library screened above (50 filters, corresponding to 1,000,000 recombinant bacteriophage) is rehybridized with this probe under stringent conditions (hybridization at 65° in standard hybridization buffer; washing at 65° in 0.2 X SSC, 0.1% SDS). All recombinants which hybridize to the bovine genomic probe which do not hybridize to the Class II probe are picked and plaque purified (10 recombinants). Plate stocks are made and small scale bacteriophage DNA preparations made. After subcloning into M13, sequence analysis indicates that 4 of these represent clones which overlap the original Class I clone. One of these, lambda U2OS-39, contains an approximately 1.5 kb insert and was deposited with the ATCC on June 16, 1987 under accession number 40345. The partial DNA sequence (compiled from lambda U2OS-39 and several other hBMP-2 Class I cDNA recombinants) and derived amino acid sequence are shown below in Table III. Lambda U2OS-39 is expected to contain all of the nucleotide sequence necessary to encode the entire human counterpart of the protein BMP-2 Class I encoded by the bovine gene segment whose partial sequence is presented in Table II. This human cDNA hBMP-2 Class I contains an open reading frame of 1188 bp, encoding a protein of 396 amino acids. This protein of 396 amino acids has a molecular weight of 45kd based on this amino acid sequence. It is contemplated that this sequence represents the primary translation product. The protein is preceded by a 5' untranslated region of 342 bp with stop codons in all frames. The 13 bp region preceding this 5' untranslated region represents a linker used in the cDNA cloning procedure.

35

40

45

50

55

TABLE III

5

10 20 30 40 50 60 70
 GTGAGCTCTA GACTGTGTGT CAGCACTTGG CTGGGGACITC TTGAACTTG CAGGGAGAAT AACATTGCGA

10

80 90 100 110 120 130 140
 CCCACATTTG CGCGGGTGCC TTTGCCCGAG CGGAGCTGC TTGCGCATCT CGAGCGCGA CGCGCGCTCC

15

150 160 170 180 190 200 210
 ACTCTCTGGC CTTGCCCCGAC ACTGAGAOGC TGTTOCCAGC GTGAAAAGAG AGACTGCGCG CGCGGCACCC

20

220 230 240 250 260 270 280
 GGGAGAAGGA CGAGGCAAAG AAAAGGAACG GACATTOGGT CCTTGCGCGA GGTCCCTTGA CCAGAGTTT

290 300 310 320 330 340 350
 TCCATGTGGA CGCTCTTCA ATGGACGTGT CCCCGCGTGC TTCTTAGACG GACTGGCGTC TCCAAAGGT

25

(1) 370 385 400
 CGACC ATG GTG GCG GGG ACG ACC CGC TGT CTT CTA CGG TTG CTG CTT CCC CAG GTC
 MET Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Leu Pro Gln Val

30

415 430 445
 CTC CTG GGC GGC GCG GCT GGC CTC GTT CGG CAG CTG GGC CGC AGG AAG TTC GCG
 Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala

35

460 475 490 505
 GCG GCG TCG TCG CGC CGC CGC TCA TOC CAG CGC TCT GAC GAG GTC CTG AGC GAG
 Ala Ala Ser Ser Gly Arg Pro Ser Ser Gln Pro Ser Asp Glu Val Leu Ser Glu

40

520 535 550 565
 TTC GAG TTG CGG CTG CTC AGC ATG TTC GGC CTG AAA CAG AGA CGC ACC CGC AGC
 Phe Glu Leu Arg Leu Leu Ser MET Phe Gly Leu Lys Gln Arg Pro Thr Pro Ser

45

580 595 610
 AGG GAC GCG GTG GTG CGC CGC TAC ATG CTA GAC CTG TAT CGC AGG CAC TCG GGT
 Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly

50

625 640 655 670
 CAG CGG GGC TCA CGC CGC CCA GAC CAC CGG TTG GAG AGG GCA GCC AGC CGA CGC
 Gln Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala

685 700 715
 AAC ACT GTG CGC AGC TTC CAC CAT GAA GAA TCT TTG GAA GAA CTA CCA GAA ACG
 Asn Thr Val Arg Ser Phe His His Glu Ser Leu Glu Glu Leu Pro Glu Thr

55

730 745 760 775
 AGT GGG AAA ACA ACC CGG AGA TTC TTC TTT AAT TTA AGT TCT ATC CTC ACG GAG
 Ser Gly Lys Thr Thr Arg Arg Phe Phe Asn Leu Ser Ser Ile Pro Thr Glu
 5 790 805 820 835
 GAG TTT ATC ACC TCA GCA GAG CTT CAG GTT TTC CGA GAA CAG ATG CAA GAT GCT
 Glu Phe Ile Thr Ser Ala Glu Leu Gln Val Phe Arg Glu Gln MET Gln Asp Ala
 10 850 865 880
 TTA GGA AAC AAT AGC AGT TTC CAT CAC CGA ATT AAT ATT TAT GAA ATC ATA AAA
 Leu Gly Asn Asn Ser Ser Phe His His Arg Ile Asn Ile Tyr Glu Ile Ile Lys
 15 895 910 925 940
 CCT GCA ACA GCA AAC TOG AAA TTC COC GTG ACC AGT CTT TTG GAC ACC AGG TTG
 Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Leu
 20 955 970 985
 GTG AAT CAG AAT GCA AGC AGG TGG GAA AGT TTT GAT GTC ACC COC GCT GTG ATG
 Val Asn Gln Asn Ala Ser Arg Trp Glu Ser Phe Asp Val Thr Pro Ala Val MET
 25 1000 1015 1030 1045
 CCG TGG ACT GCA CAG GGA CAC GGC AAC CAT GGA TTC GTG GTG GAA GTG GCC CAC
 Arg Trp Thr Ala Gln Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His
 30 1060 1075 1090 1105
 TTG GAG GAG AAA CAA GGT GTC TCC AAG AGA CAT GTT AGG ATA AGC AGG TCT TTG
 Leu Glu Glu Lys Gln Gly Val Ser Lys Arg His Val Arg Ile Ser Arg Ser Leu
 35 1120 1135 1150
 CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTC GTC ACT TTT GGC
 His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu Val Thr Phe Gly
 40 1165 1180 1195 1210
 CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GCC AAA CAC
 His Asp Gly Lys Gly His Pro Leu His Lys Arg Glu Lys Arg Gln Ala Lys His
 45 1225 1240 1255
 AAA CAG CGG AAA CGC CCT AAG TCC AGC TGT AAG AGA CAC CCT TTG TAC GTG GAC
 Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp
 50 1270 1285 1300 1315
 TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT GTG GCT CCC CGG GGG TAT CAC GCC
 Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala
 55 1330 1345 1360 1375
 TTT TAC TGC CAC GGA GAA TGC CCT TTT CCT CTG GCT GAT CAT CTG AAC TCC ACT
 Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr
 60 1390 1405 1420
 AAT CAT GGC ATT GTT CAG ACG TTG GTC AAC TCT GTT AAC TCT AAG ATT CCT AAG
 Asn His Ala Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Ile Pro Lys

1435	1450	1465	1480			
GCA TGC TGT GTC CGG ACA GAA CTC AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG						
Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser MET Leu Tyr Leu Asp Glu						
5						
1495	1510	1525				
AAT GAA AAG GTT GTA TTA AAG AAC TAT CAG GAC ATG GTG GAG GGT TGT CGG						
Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp MET Val Val Glu Gly Cys Gly						
10						
1540(396)	1553	1563	1573	1583	1593	1603
TGT CGC TAGTACAGCA AAATTAAATA CATAAATATA TATATATATA TATATTITAG AAAAAGAAA						
Cys Arg						

15 **AAAA**

Full-length hBMP-2 Class II human cDNA clones are obtained in the following manner. The 200 bp EcoRI-SacI fragment from the 5' end of the Class II recombinant II-10-1 is isolated from its plasmid subclone, labeled by nick-translation, and hybridized to a set of duplicate nitrocellulose replicas of the U-2 OS cDNA library (25 filters/set; representing 500,000 recombinants). Hybridization and washing are performed under stringent conditions as described above. 16 duplicate positives are picked and replated for secondaries. Nitrocellulose filter replicas of the secondary plates are made and hybridized to an oligonucleotide which was synthesized to correspond to the sequence of II-10-1 and is of the following sequence:

25 **CGGGCGCTCAGGATACTCAAGACCAGTGCTG**

Hybridization is in standard hybridization buffer at 50°C with washing at 50° in 1 X SSC, 0.1% SDS. 14 recombinant bacteriophages which hybridize to this oligonucleotide are plaque purified. Plate stocks are made and small scale bacteriophage DNA preparations made. After subcloning 3 of these into M13, sequence analysis indicates that they represent clones which overlap the original Class II clone. One of these, lambda U2OS-3, was deposited with the ATCC 30 under accession number 40342 on June 16, 1987. U2OS-3 contains an insert of approximately 1.8 kb. The partial DNA sequence and derived amino acid sequence of U2OS-3 are shown below in Table IV. This clone is expected to contain all of the nucleotide sequence necessary to encode the entire human BMP-2 Class II protein. This cDNA contains an open reading frame of 1224 bp, encoding a protein of 408 amino acids, preceded by a 5' untranslated region of 394 bp with stop codons in all frames, and contains a 3' untranslated region of 308 bp following the in-frame stop codon. 35 The 8 bp region preceding the 5' untranslated region represents a linker used in the cDNA cloning procedure. This protein of 408 amino acids has molecular weight of 47kd and is contemplated to represent the primary translation product.

40

45

50

55

TABLE IV

10 20 30 40 50 60 70
 5 CTCCTAGAGGG CAGAGGAGGA GGGAGGGAGG GAAGGGAGGC GGAGCCCGGC CGCGAAGCTA GGTGAGTGIG

80 90 100 110 120 130 140
 10 GCATTOOGAGC TGAGGGAGC GAGOCCTGAGA CGCGCTGCTG GCTTGGCTG AGTATCTAGC TTGTCCTOOC

150 160 170 180 190 200 210
 15 GATGGGATTG CGCTCAAGC TATCTGAGC CTGCAGAGC ACAGTCCCCG GCGCTGGGCC AGGTTTACCTG

220 230 240 250 260 270 280
 20 CAACCGTTCA GAGGTCCCA GGAGCTGCTG CTGGGAGGC CGCTACTGCA GGGACCTATG GAGCCATTCC

290 300 310 320 330 340 350
 25 GIAGTGCCAT CGCGAGAAC GCACTGCTG AGCTTCCCTG AGCTTTCCA GCAAGTTTGT TCAAGATTTG

360 370 380 390 400 (1)
 25 CTGTCAGAA TCATGGACTG TTATTTATATG CCTTGTTCCTG TGTCAAGACA CC ATG ATT CCT
 25 MET Ile Pro

417 432 447 462
 30 GGT AAC CGA ATG CTG ATG GTC GTT TTA TGA CAA GTC CTG CTA GGA GGC GCG
 Gly Asn Arg MET Leu Val Val Leu Leu Cys Gln Val Leu Gly Gly Ala

477 492 507
 35 AGC CAT GCT AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GCC GAG ATT CAG
 Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Val Ala Glu Ile Gln

522 537 552 567
 35 GGC CAC GCG GGA CGA CGC CGC TCA GGG CAG AGC CAT GAG CTC CTG CGG GAC TTC
 Gly His Ala Gly Arg Ser Gly Gln Ser His Glu Leu Leu Arg Asp Phe

582 597 612 627
 40 GAG GCG ACA CTT CTG CAG ATG TTT GCG CTG CGC CGC CGG CAG OCT AGC AAG
 Glu Ala Thr Leu Ile Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys

642 657 672
 45 AGT GCC GTC ATT CGG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT GGG GAG
 Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu

687 702 717 732
 50 GAG GAG GAA GAG CAG ATC CAG AGC ACT CGT CTT GAG TAT CCT GAG CGC CGG GCG
 Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala

55

747 762 777
 AGC CGG GGC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC
 Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile
 5 792 807 822 837
 CCA GGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC
 Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile
 10 852 867 882 897
 CCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TTC CGG GAG CAG GTG
 Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val
 15 912 927 942
 GAC CAG GGC CCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT TAT GAG GTT
 Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val
 20 957 972 987 1002
 ATG AAG CCC CCA GCA GAA GTG GTG CCT GGG CAC CTC ATC ACA CGA CTA CTG GAC
 MET Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp
 1017 1032 1047
 ACG AGA CTG GTC CAC CAC AAT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCT
 Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro
 25 1062 1077 1092 1107
 GCG GTC CTT CGC TGG ACC CGG GAG AAG CAG CCA AAC TAT GGG CTA GCC ATT GAG
 Ala Val Leu Arg Trp Thr Arg Glu Lys Pro Asn Tyr Gly Leu Ala Ile Glu
 1122 1137 1152 1167
 GTG ACT CAC CTC CAT CAG ACT CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT AGC
 Val Thr His Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser
 35 1182 1197 1212
 CGA TCG TTA CCT CAA GGG AGT GGG AAT TGG GCC CAG CTC CGG CCC CTC CTG GTC
 Arg Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu Val
 1227 1242 1257 1272
 ACC TTT GGC CAT GAT GGC CGG GGC CAT GCC TTG ACC CGA CGC CGG AGG GGC AAG
 Thr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg Arg Ala Lys
 40 1287 1302 1317
 CGT AGC CCT AAG CAT CAC TCA CAG CGG GCC AGG AAG AAG AAT AAC AAC TGC CGG
 Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg
 1332 1347 1362 1377
 CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC TGG ATT GTG
 Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val
 50 1392 1407 1422 1437
 GCC CCA CCA CGC TAC CAG GGC TTC TAC TGC CAT GGG GAC TGC CGC TTT CCA CTG
 Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gly Asp Cys Pro Phe Pro Leu

1452 1467 1482

GCT GAC CAC CTC AAC TCA ACC AAC CAT GCC ATT GTG CAG ACC CTG GTC AAT TCT
Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser

5 1497 1512 1527 1542

GTC AAT TCC AGT ATC CCC AAA GCC TGT TGT GTG CCC ACT GAA CTG AGT GCC ATC
Val Asn Ser Ser Ile Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile

10 1557 1572 1587

TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG GTG GTA CTG AAA AAT TAT CAG GAG
Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu

15 1602 1617 (408) 1636 1646 1656

ATG GTA GTA GAG CGA TGT CGG TGC CGC TGAGATCAGG CAGTOCTTGA GGATAGACAG
15 MET Val Val Glu Gly Cys Arg

1666 1676 1686 1696 1706 1716 1726

ATATACACACAC CACACACACA CACCATACAC ACCACACACA CACGTTOCCA TOCACCTAAC CACACACTAC

20 1736 1746 1756 1766 1776 1786 1796

ACAGACATGCT TCCCTATAGC TGGACTTTTA TTAAAAAAA AAAAAAAA AATGGAAAAA ATCCCTAAC

25 1806 1816 1826 1836 1846 1856 1866

ATTCAACCTTG ACCTTATTTA TGACTTTACG TCCAAATGTT TTGACCATAT TGATCATATA TTITGACAAA

30 1876 1886 1896 1906 1916 1926 1936

ATATATTTAT AACTACGTAT TAAAGAAAA AAATAAAATG AGTCATTATT TTAAAAAAA AAAAAAAACT

35 1946

C TAGAGT GCA CGGAATTC

The sequences of BMP-2 Class I and II as shown in Tables II, III IV and have significant homology to the beta (B) and beta (A) subunits of the inhibins. The inhibins are a family of hormones which are presently being investigated for use in contraception. See, A. J. Mason et al., *Nature*, 318:659-663 (1985). To a lesser extent they are also homologous to Mullerian inhibiting substance (MIS), a testicular glycoprotein that causes regression of the Mullerian duct during development of the male embryo and transforming growth factor-beta (TGF- β) which can inhibit or stimulate growth of cells or cause them to differentiate. Furthermore, the sequence of Table IV encoding hBMP-2 Class II has significant homology to the *Drosophila* decapentaplegic (DPP-C) locus transcript. See, J. Massague, *Cell*, 49:437-438 (1987); R. W. Padgett et al., *Nature*, 325:81-84 (1987); R.L. Cate et al., *Cell* 45: 685-698 (1986). It is considered possible therefore that BMP-2 Class II is the human homolog of the protein made from this transcript form this developmental mutant locus.

EXAMPLE VI

Expression of Bone Inductive Factors.

In order to produce bovine, human or other mammalian bone inductive factors, the DNA encoding it is transferred into an appropriate expression vector and introduced into mammalian cells by conventional genetic engineering techniques.

One skilled in the art can construct mammalian expression vectors by employing the sequence of Tables II, III AND IV or other modified sequences and known vectors, such as pCD [Okayama et al., *Mol. Cell Biol.*, 2:161-170 (1982)] and pJL3, pJL4 [Gough et al., *EMBO J.*, 4:645-653 (1985)]. The transformation of these vectors into appropriate host cells can result in expression of osteoinductive factors. One skilled in the art could manipulate the sequences of Tables II, III and IV by eliminating or replacing the mammalian regulatory sequences flanking the coding sequence with bacterial sequences to create bacterial vectors for intracellular or extracellular expression by bacterial cells. For ex-

ample, the coding sequences could be further manipulated (e.g. ligated to other known linkers or modified by deleting non-coding sequences therefrom or altering nucleotides therein by other known techniques). The modified bone inductive factor coding sequence could then be inserted into a known bacterial vector using procedures such as described in T. Taniguchi et al., Proc. Natl Acad. Sci. USA, 77:5230-5233 (1980). This exemplary bacterial vector could then be 5 transformed into bacterial host cells and bone inductive factor expressed thereby. For a strategy for producing extracellular expression of bone inductive factor in bacterial cells., see, e.g. European patent application EPA 177,343.

Similar manipulations can be performed for the construction of an insect vector [see, e.g. procedures described 10 in published European patent application 155,476] for expression in insect cells. A yeast vector could also be constructed employing yeast regulatory sequences for intracellular or extracellular expression of the factors of the present invention by yeast cells. [See, e.g., procedures described in published PCT application W086/00639 and European patent application EPA 123,289].

A method for producing high levels of an osteoinductive factor of the invention from mammalian cells involves the 15 construction of cells containing multiple copies of the heterologous bone inductive factor gene. The heterologous gene can be linked to an amplifiable marker, e.g. the dihydrofolate reductase (DHFR) gene for which cells containing increased gene copies can be selected for propagation in increasing concentrations of methotrexate (MTX) according to the procedures of Kaufman and Sharp, J. Mol. Biol., 159:601-629 (1982). This approach can be employed with a number of different cell types.

For example, a plasmid containing a DNA sequence for a bone inductive factor of the invention in operative association 20 with other plasmid sequences enabling expression thereof and the DHFR expression plasmid pAdA26SV(A) 3 [Kaufman and Sharp, Mol. Cell. Biol., 2:1304 (1982)] can be co-introduced into DHFR-deficient CHO cells, DUKX-BII, by calcium phosphate coprecipitation and transfection. DHFR expressing transformants are selected for growth in alpha media with dialyzed fetal calf serum, and subsequently selected for amplification by growth in increasing concentrations of MTX (sequential steps in 0.02, 0.2, 1.0 and 5uM MTX) as described in Kaufman et al., Mol Cell Biol., 5: 25 1750 (1983). Transformants are cloned, and biologically active bone inductive factor expression is monitored by rat bone formation assay. Bone inductive factor expression should increase with increasing levels of MTX resistance. Similar procedures can be followed to produce other bone inductive factors.

Alternatively, the human gene is expressed directly, as described above. Active bone inductive factor may be produced in bacteria or yeast cells. However the presently preferred expression system for biologically active recombinant human bone inductive factor is stably transformed CHO cells.

As one specific example, to produce the human bone inductive factor (hBMP-1) of Example V, the insert of U2OS-1 30 is released from the vector arms by digestion with Sal I and subcloned into the mammalian expression vector pMT2CX digested with Xho I. Plasmid DNA from this subclone is transfected into COS cells by the DEAE-dextran procedure [Sompayrac and Danna PNAS 78:7575-7578 (1981); Luthman and Magnusson, Nucl. Acids Res. 11: 1295-1308 (1983)]. Serum-free 24 hr. conditioned medium is collected from the cells starting 40-70 hr. post-transfection.

The mammalian expression vector pMT2 Cla-Xho (pMT2 CX) is a derivative of p91023 (b) (Wong et al., Science 228:810-815, 1985) differing from the latter in that it contains the ampicillin resistance gene in place of the tetracycline 35 resistance gene and further contains a Xhol site for insertion of cDNA clones. The functional elements of pMT2 Cla-Xho have been described (Kaufman, R.J., 1985, Proc. Natl. Acad. Sci. USA 82:689-693) and include the adenovirus VA genes, the SV40 origin of replication including the 72 bp enhancer, the adenovirus major late promoter including a 40 5' splice site and the majority of the adenovirus tripartite leader sequence present on adenovirus late mRNAs, a 3' splice acceptor site, a DHFR insert, the SV40 early polyadenylation site (SV40), and pBR322 sequences needed for propagation in E. coli.

Plasmid pMT2 Cla-Xho is obtained by EcoRI digestion of pMT2-VWF, which has been deposited with the American 45 Type Culture Collection (ATCC), Rockville, MD (USA) under accession number ATCC 67122. EcoRI digestion excises the cDNA insert present in pMT2-VWF, yielding pMT2 in linear form which can be ligated and used to transform E. coli HB 101 or DH-5 to ampicillin resistance. Plasmid pMT2 DNA can be prepared by conventional methods. pMT2CX is then constructed by digesting pMT2 with Eco RI and XbaI, treating the digested DNA with Klenow fragment of DNA polymerase I, and ligating Cla linkers (NEBiolabs, CATCGATG). This removes bases 2266 to 2421 starting from the Hind III site near the SV40 origin of replication and enhancer sequences of pMT2. Plasmid DNA is then digested with 50 EcoRI, blunted as above, and ligated to an EcoRI adapter,

5' PO₄-AATTCCCTCGAGAGCT 3'

3' GGAGCTCTCGA 5'

digested with Xhol, and ligated, yielding pMT2 Cla-Xho, which may then be used to transform E. coli to ampicillin resistance. Plasmid pMT2 Cla-Xho DNA may be prepared by conventional methods.

Example VIIBiological Activity of Expressed Bone Inductive Factor

5 A. BMP-1

To measure the biological activity of the expressed bone inductive factor, (hBMP-1) obtained in Example VI above. The factor is partially purified on a Heparin Sepharose column. 4 ml of transfection supernatant from one 100 mm dish is concentrated approximately 10 fold by ultrafiltration on a YM 10 membrane and then dialyzed against 20mM Tris, 10 0.15 M NaCl, pH 7.4 (starting buffer). This material is then applied to a 1.1 ml Heparin Sepharose column in starting buffer. Unbound proteins are removed by an 8 ml wash of starting buffer, and bound proteins, including BMP-1, are desorbed by a 3-4 ml wash of 20 mM Tris, 2.0 M NaCl, pH 7.4.

The proteins bound by the Heparin column are concentrated approximately 10-fold on a Centricon 10 and the salt reduced by diafiltration with 0.1% trifluoroacetic acid. The appropriate amount of this solution is mixed with 20 mg of rat matrix and then assayed for *in vivo* bone and cartilage formation as previously described in Example III. A mock transfection supernatant fractionation is used as a control.

20 The implants containing rat matrix to which specific amounts of human BMP-1 have been added are removed from rats after seven days and processed for histological evaluation. Representative sections from each implant are stained for the presence of new bone mineral with von Kossa and acid fuchsin, and for the presence of cartilage-specific matrix formation using toluidine blue. The types of cells present within the section, as well as the extent to which these cells display phenotype are evaluated.

25 Addition of human BMP-1 to the matrix material resulted in formation of cartilage-like nodules at 7 days post implantation. The chondroblast-type cells were recognizable by shape and expression of metachromatic matrix. The amount of activity observed for human BMP-1 was dependent upon the amount of human BMP-1 protein added to the matrix. Table IX illustrates the dose-response relationship of human BMP-1 protein to the amount of bone induction observed.

Table IX

IMPLANT NUMBER	AMOUNT USED (equivalent of ml transfection media)	HISTOLOGICAL SCORE
876-134-1	10 BMP-1	C+2
876-134-2	3 BMP-1	C+1
876-134-3	1 BMP-1	C+/-
876-134-4	10 MOCK	C-
876-134-5	3 MOCK	C -
876-134-6	1 MOCK	C -

Cartilage (c) activity was scored on a scale from 0(-) to 5.

40 Similar levels of activity are seen in the Heparin Sepharose fractionated COS cell extracts. Partial purification is accomplished in a similar manner as described above except that 6 M urea is included in all the buffers. Further, in a rat bone formation assay as described above, BMP-2 has similarly demonstrated chondrogenic activity.

45 The procedures described above may be employed to isolate other bone inductive factors of interest by utilizing the bovine bone inductive factors and/or human bone inductive factors as a probe source. Such other bone inductive factors may find similar utility in, *inter alia*, fracture repair.

The foregoing descriptions detail presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descriptions. Those modifications and variations are believed to be encompassed within the claims appended hereto.

50 **Claims**

Claims for the following Contracting States: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

55 1. A gene encoding human BMP-2 comprising the following DNA sequence:

10 20 30 40 50 60 70
 GTOGACTCTA GAGTGTGTGT CAGCACTTGG CTGGGGACITI CITGAACITG CAGGGAGAAAT AACITGCGCA
 5
 80 90 100 110 120 130 140
 CCCACITTG CGCGGGTGC TTTGCCCCAG OGGAGCTGC TTGCGCATCT CGAGGCCCCA CGCGGGCTOC
 10 150 160 170 180 190 200 210
 ACTCCTCGGC CITGCCCGAC ACTGAGAOGC TGTTOCAGC GTGAAAAGAG AGACTGCGCG GCGGGCACCC
 15 220 230 240 250 260 270 280
 GGGAGAAGGA GGAGGCAAAG AAAAGGAAACG GACATTGGT CCTTGCGCCA GGTCCTTGA CCAGAGTTT
 20 290 300 310 320 330 340 350
 TCCATGTGGA CGCTCTTCA ATGGAGTGT CCCCGCTGC TTCITAGAOG GACTGCGGTC TCCCTAAAGGT
 (1) 370 385 400
 CGACC ATG GTG GGC GGG ACC CGC TGT CTT CTA CGG TTG CTG CTT ACC CAG GTC
 MET Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Pro Gln Val
 25 415 430 445
 CTC CTG GGC GGC GCG GCT GGC CTC GTT COG GAG CTG GGC CGC AGG AAG TTC GCG
 Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala
 30 460 475 490 505
 GCG GCG TOG TOG GGC CGC ACC TCA TCC CAG CGC TCT GAC GAG GTC CTG AGC GAG
 Ala Ala Ser Ser Gly Arg Pro Ser Ser Gln Pro Ser Asp Glu Val Leu Ser Glu
 35 520 535 550 565
 TTC GAG TTG CGG CTG CTC AGC ATG TTC GGC CTG AAA CAG AGA CGC ACC ACC CGC
 Phe Glu Leu Arg Leu Ser MET Phe Gly Leu Lys Gln Arg Pro Thr Pro Ser
 40 580 595 610
 AGG GAC CGC GTG GTG CGC ACC TAC ATG CTA GAC CTG TAT CGC AGG CAC TOG GGT
 Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly
 45 625 640 655 670
 CAG CGG GGC TCA CGC CGC CCA GAC CAC CGG TTG GAG AGG GCA GCC AGC CGA CGC
 Gln Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala
 50 685 700 715
 AAC ACT GTG CGC AGC TTC CAC CAT GAA GAA TCT TTG GAA GAA CTA CCA GAA ACG
 Asn Thr Val Arg Ser Phe His His Glu Glu Ser Leu Glu Glu Leu Pro Glu Thr

50

55

730 745 760 775
 AGT GGG AAA ACA ACC OGG AGA TTC TTC TTT AAT TTA AGT TCT ATC CCC ACG GAG
 Ser Gly Lys Thr Thr Arg Arg Phe Phe Asn Leu Ser Ser Ile Pro Thr Glu
 5

790 805 820 835
 GAG TTT ATC ACC TCA GCA GAG CTT CAG GTT TTC CGA GAA CAG ATG CAA GAT GCT
 Glu Phe Ile Thr Ser Ala Glu Leu Gln Val Phe Arg Glu Gln MET Gln Asp Ala
 10

850 865 880
 TTA GGA AAC AAT AGC AGT TTC CAT CAC CGA ATT AAT ATT TAT GAA ATC ATA AAA
 Leu Gly Asn Asn Ser Ser Phe His His Arg Ile Asn Ile Tyr Glu Ile Ile Lys

15 895 910 925 940
 CCT GCA ACA GCC AAC TCG AAA TTC CCC GTG ACC AGT CTT TTG GAC ACC AGG TTG
 Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Leu

20 955 970 985
 GTG AAT CAG AAT GCA AGC AGG TGG GAA AGT TTT GAT GTC ACC CCC GCT GTG ATG
 Val Asn Gln Asn Ala Ser Arg Trp Glu Ser Phe Asp Val Thr Pro Ala Val MET

25 1000 1015 1030 1045
 CCG TGG ACT GCA CAG GGA CAC GGC AAC CAT GGA TTC GTG GTG GAA GTG GOC CAC
 Arg Trp Thr Ala Gln Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His

30 1060 1075 1090 1105
 TTG GAG GAG AAA CAA GGT GTC TCC AAG AGA CAT GTT AGG ATA AGC AGG TCT TTG
 Leu Glu Glu Lys Gln Gly Val Ser Lys Arg His Val Arg Ile Ser Arg Ser Leu

35 1120 1135 1150
 CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTA GTA ACT TTT GGC
 His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu Val Thr Phe Gly

40 1165 1180 1195 1210
 CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GGC AAA CAC
 His Asp Gly His Pro Leu His Lys Arg Glu Lys Arg Gln Ala Lys His

45 1225 1240 1255
 AAA CAG CGG AAA CGC CCT AAG TCC AGC TGT AAG AGA CAC CCT TTG TAC GTG GAC
 Lys Gln Arg Lys Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp

50 1270 1285 1300 1315
 TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT GTG GCT CCC CGG GGG TAT CAC GCC
 Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala

55 1330 1345 1360 1375
 TTT TAC TGC CAC GGA GAA TGC CCT TTT CCT CTG GCT GAT CAT CTG AAC TCC ACT
 Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr

55 1390 1405 1420
 AAT CAT GCC ATT GTT CAG ACG TTG GTC AAC TCT GTT AAC TCT AAG ATT CCT AAG
 Asn His Ala Ile Val Gln Thr Leu Val Asn Ser Val Lys Ile Pro Lys

1435 1450 1465 1480
 GCA TGC TGT GTC CGC ACA GAA CTC AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG
 Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser MET Leu Tyr Leu Asp Glu

5 1495 1510 1525
 AAT GAA AAG GTT GTC TTA AAG AAC TAT CAG GAC ATG GTT GTG GAG GGT TGT GGG
 Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp MET Val Val Glu Gly Cys Gly

10 1540(396) 1553 1563 1573 1583 1593 1603
 TGT CGC TAGTACAGCA AAAATTAAATA CATAAATATA TATATATATA TATATTTAG AAAAAAGAAA
 Cys Arg

15 **AAAAA**

2. A gene encoding human BMP-2 having the amino acid sequence given in claim 1.
3. A gene encoding a protein exhibiting properties of human BMP-2 and comprising a DNA sequence:
 20 (a) which differs from a DNA sequence of claim 1 in codon sequence due to the degeneracy of the genetic code;
 (b) which hybridises with a DNA sequence of claim 1 or section (a), above; or
 (c) represents a fragment, allelic or other variation of a DNA sequence of claim 1, whether said variation results in changes in the peptide sequence or not.
4. The DNA sequence of claim 3, which is a genomic DNA sequence.
 25 5. The DNA sequence of claim 3, which is a cDNA sequence.
- 30 6. A gene encoding bovine BMP-2 comprising the following DNA sequence:

35

40

45

50

55

(1) 15 30 45
 GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG
 G H D G K G H P L H R R E K R

5 60 75 90
 CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG
 Q A K H K Q R K R L K S S C K

10 105 120 135
 AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC
 R H P L Y V D F S D V G W N D

15 150 165 180
 TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG
 W I V A P P G Y H A F Y C H G

20 195 210 225
 GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT
 E C P F P L A D H L N S T N H

25 240 255 270
 GCC ATT CTC CAA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC
 A I V Q T L V N S V N S K I P

30 330 345 360
 TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC
 Y L D E N E K V V L K N Y Q D

35 375 (129) 397 407
 ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAAATA
M V V E G C G C R

40 417 427 437 447 457
 TAAATATATA TATATATATA TTAGAAAAAC AGCAAAAAAA TCAAGTTGAC

45 467 477 487 497 507
 ACTTTAATAT TTCCCAATGA AGACTTTATT TATGGAATGG AATGGAGAAA

50 517 527 537 547 557
 AAGAAAAACA CAGCTATTTT GAAAACATA TTTATATCTA CCGAAAAGAA

55 567 577 587
 GTTGGGAAAA CAAATATTTT AATCAGAGAA TTATT

- 50 7. A gene encoding bovine BMP-2 containing the amino acid sequence of claim 6.
8. A gene encoding a protein exhibiting properties of bovine BMP-2 and comprising DNA sequences:
- (a) which differ from a DNA sequence of claim 7 in codon sequence due to the degeneracy of the genetic code;
- 55 (b) which hybridise with a DNA sequence of claim 7 or section (a), above; or
- (c) represent fragments, allelic or other variations of a DNA sequence of claim 7, whether said variations result in changes in the peptide sequence or not.

9. The DNA sequence of claim 8, which is a genomic DNA sequence.
10. The DNA sequence of claim 8, which is a cDNA sequence.
- 5 11. A gene encoding human BMP-4 comprising the following DNA sequence:

10	10	20	30	40	50	60	70
	CCTAGACGG	CAGAGGAGGA	GGGAGGGAGG	CAAGGAGOGC	GGAGCCCGGC	<u>COGGAAGCTA</u>	GGTGAGTGIG
15	80	90	100	110	120	130	140
	GCATCOGAGC	TGAGGGAOGC	GAGOCTGAGA	OGOOGCTGCT	GCTCOGGCTG	AGTATCTAGC	TTGTCTOCCC
20	150	160	170	180	190	200	210
	GATGGGATTTC	COGTCCAAGC	TATCTOGAGC	CTGCCAGAGGC	ACAGTCCCGG	GOOCCTGOCG	AGGTTCACTG
25	220	230	240	250	260	270	280
	CAACCGITCA	GAGGTCCCCA	GGAGCTGCTG	CTGGGAGGCC	CGCTACTGCA	GGGAOctATG	GAGCCATTCC
30	290	300	310	320	330	340	350
	GTAGTGCAT	CCCGAGCAAC	GCACTGCTGC	AGCCTCCCTG	AGCCTTTCCA	GCAAGTTTGT	TCAAGATTGG
35	360	370	380	390	400	(1)	
	CTGTCAAGAA	TCATGGACTG	TTATTTATAAG	CTTGTGTTTC	TGTCAAGACA	CC ATG ATT CCT	MET Ile Pro

40

45

50

55

417 432 447 462
 GGT AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA GGA CCC GCG
 Gly Asn Arg MET Leu MET Val Val Leu Leu Cys Gln Val Leu Leu Gly Gly Ala
 5

477 492 507
 AGC CAT GCT AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GOC GAG ATT CAG
 Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Lys Val Ala Glu Ile Gln

522 537 552 567
 GGC CAC GCG GGA GGA CGC CGC TCA GGG CAG AGC CAT GAG CTC CTG CGG GAC TTC
 Gly His Ala Gly Arg Arg Ser Gly Gln Ser His Glu Leu Leu Arg Asp Phe

582 597 612 627
 10 GAG CGG ACA CTT CTG CAG ATG TTT GGG CTG CGC CGC CGC CGC CAG CCT AGC AAG
 Glu Ala Thr Leu Leu Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys

642 657 672
 15 AGT GOC GTC ATT CGG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT CGG GAG
 Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu

687 702 717 732
 20 GAG GAG GAA GAG CAG ATC CAC AGC ACT GGT CTT GAG TAT CCT GAG CGC CGC GOC
 Glu Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala

747 762 777
 25 AGC CGG GOC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC
 Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile

792 807 822 837
 30 CCA CGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC
 Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile

852 867 882 897
 35 OCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TTC CGG GAG CAG GTG
 Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val

912 927 942
 GAC CAG GGC CCT GAT TGG GAA AGG CGC TTC CAC CGT ATA AAC ATT TAT GAG GTT
 Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val

957 972 987 1002
 40 ATG AAG CCC CCA GCA GAA GTG GTG CCT GGG CAC CTC ATC ACA CGA CTA CTG GAC
 MET Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp

1017 1032 1047
 45 ACG AGA CTG GTC CAC CAC AAT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCT
 Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro

1062 1077 1092 1107
 50 GCG GTC CTT CGC TGG ACC CGG GAG AAG CAG CCA AAC TAT GGG CTA GGC ATT GAG
 Ala Val Leu Arg Trp Thr Arg Glu Lys Gln Pro Asn Tyr Gly Leu Ala Ile Glu

1122 1137 1152 1167
 55 GTG ACT CAC CTC CAT CAG ACT CGG ACC CAC CAG CGC CAG CAT GTC AGG ATT AGC
 Val Thr His Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser

1182 1197 1212
 CGA TCG TTA OCT CAA GGG AGT GGG AAT TGG GGC CAG CTC CGG CCC CTC CTG GTC
 5 Arg Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu Val
 1227 1242 1257 1272
 AOC TTT GGC CAT GAT GGC CGG GGC CAT GGC TTG AOC CGA CGC CGG AGG GGC AAG
 Thr Phe Gly His Asp Gly Arg His Ala Leu Thr Arg Arg Arg Ala Lys
 10 1287 1302 1317
 CGT AGC CCT AAG CAT CAC TCA CAG CGG GGC AGG AAG AAG AAT AAC TGC CGG
 Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Asn Cys Arg
 15 1332 1347 1362 1377
 CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC TGG ATT GTG
 Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val
 20 1392 1407 1422 1437
 GCC CCA CCA GGC TAC CAG GCC TTC TAC TGC CAT CGG GAC TGC CCC TTT CCA CTG
 Ala Pro Pro Glv Tvr Gln Ala Phe Tvr Cvs His Glv Asn Cvs Pro Phe Pro Leu
 25 1452 1467 1482
 GCT GAC CAC CTC AAC TCA ACC AAC CAT GCC ATT GTG CAG ACC CTG GTC AAT TCT
 Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser
 30 1497 1512 1527 1542
 GTC AAT TCC AGT ATC CCC AAA GCC TGT TGT GTG CCC ACT GAA CTG AGT GGC ATC
 Val Asn Ser Ser Ile Pro Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile
 35 1557 1572 1587
 TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG GTG GTA CTG AAA AAT TAT CAG GAG
 Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu
 40 1602 1617 (408) 1636 1646 1656
 ATG GTA GTA GAG GGA TGT GGG TGC CGC TGAGATCAGG CAGTCCTTGA GGATAGACAG
 MET Val Val Glu Gly Cys Gly Cys Arg
 45 1666 1676 1686 1696 1706 1716 1726
 ATATACACAC CACACACACA CACCACATAC ACCACACACA CACGTTCCA TOCACTCACC CACACACTAC
 50 1736 1746 1756 1766 1776 1786 1796
 ACAGACTGCT TCCCTATAGC TGGACTTTTA TTAAAAAAA AAAAAAAA AATGGAAAAA ATCCCTAAC
 55 1806 1816 1826 1836 1846 1856 1866
 ATTCAACCTTG ACCTTATTAA TGACCTTACG TGCAAAATGT TTGACCATAT TGATCATATA TTGACACAA
 60 1876 1886 1896 1906 1916 1926 1936
 ATATAATTAT AACTACGTAT TAAAAGAAAA AAATAAAAATG AGTCATTATT TTAAAAAAA AAAAAAAACT
 65 1946
 CTAGAGTCGA CGGAATTC

- 55
12. A gene encoding human BMP-4 having the amino acid sequence given in claim 11.
 13. A gene encoding a protein exhibiting properties of BMP-4 and comprising a DNA sequence:

- (a) which differs from a DNA sequence of claim 11 in codon sequence due to the degeneracy of the genetic code;
(b) which hybridises with a DNA sequence of claim 11 or section (a), above; or
(c) represents a fragment, allelic or other variation of a DNA sequence of claim 11, whether said variation results in changes in the peptide sequence or not.

- 5 14. The DNA sequence of claim 13, which is a genomic DNA sequence.
10 15. The DNA sequence of claim 13, which is a cDNA sequence.
16. A vector containing the gene or DNA sequence of any one of claims 1 to 15 in operative association with an expression control sequence.
17. A cell transformed with a vector of claim 16.
18. The cell of claim 17 which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.
19. The cell of claim 18 which is a CHO cell.
20. 20. A protein exhibiting properties of BMP-2 which is encoded by a gene or DNA sequence of any one of claims 1 to 10.
21. A protein exhibiting properties of BMP-2, which is obtainable by the steps of culturing in a suitable culture medium a cell transformed with an expression vector comprising a gene or a DNA sequence of any one of claims 1 to 10, and recovering said protein from said culture medium.
25 22. A protein exhibiting properties of BMP-4 which is encoded by a gene or DNA sequence of any one of claims 11 to 15.
23. A protein exhibiting properties of BMP-4, which is obtainable by the steps of culturing in a suitable culture medium a cell transformed with an expression vector comprising a gene or a DNA sequence of any one of claims 11 to 15, and recovering said protein from said culture medium.
30 24. A process for producing the protein of claims 21 or 23, comprising the steps of culturing in a suitable culture medium the cell of claim 17 and isolating said protein from said culture medium.
35 25. A pharmaceutical composition comprising the proteins of any one of claims 20 to 23, individually or in combination, and a pharmaceutically acceptable vehicle.
26. The pharmaceutical composition of claim 25, further comprising a matrix capable of delivering the composition to the site of the bone or cartilage defect and providing a structure for inducing bone or cartilage formation.
40 27. The pharmaceutical composition of claim 26, wherein said matrix comprises hydroxyapatite, collagen, polylactic acid or tricalcium phosphate.
28. Use of a protein of any one of claims 20 to 23, individually or in combination, for the preparation of a pharmaceutical composition for inducing bone or cartilage formation.
45

Claims for the following Contracting State : AT

- 50 1. A process for the preparation of a gene encoding human BMP-2 comprising the following DNA sequence:

10 20 30 40 50 60 70

GTOGACTCTA GAGTGTGTG CAGCACTTGG CTGGGGACTT CTTGAACITG CAGGGAGAAAT AACTTGCGCA

5

80 90 100 110 120 130 140

COCCACTTTG CGGGGGTGOC TTTCGGGGAG CGGAGCTGTC TTGGCCATCT CGAGGCCCCA CGGGGGCTCC

10 150 160 170 180 190 200 210

ACTCTCTGGC CTTGGGGAGC ACTGAGAOGC TGTTCOCAGC GTGAAAAGAG AGACTGAGGAG GGCGGCACCC

15 220 230 240 250 260 270 280

GGGAGAAGGA GGAGGCAAAG AAAAGGAACG GACATTOGGT CCTTGCGCGA GGTCCTTGA CGAGAGTTT

20 290 300 310 320 330 340 350

TCCATGTGGA CGCTCTTCA ATGGAGTGT COCGAGTGC TTCTTAGAGG GACTGGGGTC TCTAAAGGT

(1) 370 385 400

CGACC ATG GTG GGC GGG ACC CGC TGT CTT CTA CGG TTG CTC CTT CGC CAG GTC
MET Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Pro Gln Val

25 415 430 445

CTC CTG GGC GGC CGT GGT CTC GTT CGG GAG CTG GGC CGC AGG AAG TTC CGG
Leu Leu Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala

30 460 475 490 505

GCG GCG TCG TCG GGC CGC CCC TCA TCC CAG CGC TCT GAC GAG GTC CTG ACC GAG
Ala Ala Ser Ser Gly Arg Pro Ser Ser Gln Pro Ser Asp Glu Val Leu Ser Glu

35 520 535 550 565

TTC GAG TTG CGG CTG CTC AGC ATG TTC GGC CTG AAA CAG AGA CGC ACC CGC ACC
Phe Glu Leu Arg Leu Leu Ser MET Phe Gly Leu Lys Gln Arg Pro Thr Pro Ser

40 580 595 610

AGG GAC GGC GTG GTG CCC CCC TAC ATG CTA GAC CTG TAT CGC AGG CAC TCG CGT
Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly

45 625 640 655 670

CAG CGG GGC TCA CCC GCC CCA GAC CAC CGG TTG GAG AGG GCA GCC AGC CGA CGC
Gln Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala

50 685 700 715

AAC ACT GTG CGC AGC TTC CAC CAT GAA GAA TCT TTG GAA GAA CTA CGA GAA ACC
Asn Thr Val Arg Ser Phe His His Glu Ser Leu Glu Glu Leu Pro Glu Thr

50

55

730 745 760 775
 AGT GGG AAA ACA ACC CGG AGA TTC TTC TTT AAT TTA AGT TCT ATC CCC ACG GAG
 Ser Gly Lys Thr Thr Arg Arg Phe Phe Asn Leu Ser Ser Ile Pro Thr Glu
 5

790 805 820 835
 GAG TTT ATC ACC TCA GCA GAG CTT CAG GTT TTC CGA GAA CAG ATG CAA GAT GCT
 Glu Phe Ile Thr Ser Ala Glu Leu Gln Val Phe Arg Glu Gln MET Gln Asp Ala
 10

850 865 880 895
 TTA GGA AAC AAT AGC AGT TTC CAT CAC CGA ATT AAT ATT TAT GAA ATC ATA AAA
 Leu Gly Asn Asn Ser Ser Phe His His Arg Ile Asn Ile Tyr Glu Ile Ile Lys
 15

955 970 985 995
 CCT GCA ACA GCC AAC TCG AAA TTC CCC GTG ACC AGT CTT TTG GAC ACC AGG TTG
 Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Leu
 20

1000 1015 1030 1045
 CGG TGG ACT GCA CAG GGA CAC GGC AAC CAT GGA TTC GTG GTG GAA GTG GCC CAC
 Arg Trp Thr Ala Gln Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His
 25

1060 1075 1090 1105
 TTG GAG GAG AAA CAA GGT GTC TCC AAG AGA CAT GTT AGG ATA AGC AGG TCT TTG
 Leu Glu Glu Lys Gln Gly Val Ser Lys Arg His Val Arg Ile Ser Arg Ser Leu
 30

1120 1135 1150 1165
 CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTA GTA ACT TTT GCC
 His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu Val Thr Phe Gly
 35

1165 1180 1195 1210
 CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GGC AAA CAC
 His Asp Gly Lys His Pro Leu His Lys Arg Glu Lys Arg Gln Ala Lys His
 40

1225 1240 1255 1270
 AAA CAG CGG AAA CGC CTT AAG TCC AGC TGT AAG AGA CAC CCT TTG TAC GTG GAC
 Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp
 45

1285 1300 1315 1330
 TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT GTG GCT CCC CGG GGG TAT CAC GCC
 Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala
 50

1345 1360 1375 1390
 TTT TAC TGC CAC GGA GAA TGC OCT TTT CCT CTG GCT GAT CAT CTG AAC TCC ACT
 Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr
 55

1405 1420
 AAT CAT GCC ATT GTT CAG ACC TTG GTC AAC TCT GTT AAC TCT AAG ATT OCT AAG
 Asn His Ala Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys

1435 1450 1465 1480
 GCA TGC TGT GTC CCG ACA GAA CTC AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG
 5 Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser MET Leu Tyr Leu Asp Glu

 1495 1510 1525
 AAT GAA AAG GTT GTA TTA AAG AAC TAT CAG GAC ATG GTG GAG GGT TGT GGG
 Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp MET Val Val Glu Gly Cys Gly
 10 1540(396) 1553 1563 1573 1583 1593 1603
 TGT CGC TAGTACAGCA AAATTAATAA CATAAATATA TATATATATA TATATTTAG AAAAAAGAAA
 Cys Arg

15 **AAAA**,

wherein said process comprises the following steps:

- 20 a) screening of a gene library constructed from U-2 OS derived DNA or cDNA with a labelled bBMP-2 fragment by hybridization,
 - b) isolating positive clones, and
 - c) isolating the DNA-inserts from said clones.
- 25 2. The process according to claim 1, wherein the gene encodes human BMP-2 having the amino acid sequence given in claim 1.
 3. A process for the preparation of a gene encoding a protein exhibiting properties of human BMP-2 and comprising a DNA sequence:
 - 30 a) which differs from a DNA sequence of claim 1 in codon sequence due to the degeneracy of the genetic code;
 - b) which hybridizes with a DNA sequence of claim 1 or section (a), above; or
 - c) represents a fragment, allelic or other variation of a DNA sequence of claim 1, whether said variation results in changes in the peptide sequence or not,
- 35 wherein said process comprises standard techniques of molecular biology.
- 40 4. The process according to claim 3, wherein the DNA sequence is a genomic DNA sequence.
 5. The process according to claim 3, wherein the DNA sequence is a cDNA sequence.
 6. A process for the preparation of a gene encoding bovine BMP-2 comprising the following DNA sequence:

45

50

55

(1) 15 30 45
 GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG
 G H D G K G H P L H R R E K R

5 60 75 90
 CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG
 Q A K H K Q R K R L K S S C K

10 105 120 135
 AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC
 R H P L Y V D F S D V G W N D

15 150 165 180
 TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG
 W I V A P P G Y H A F Y C H G

20 195 210 225
 GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT
 E C P F P L A D H L N S T N H

25 240 255 270
 GGC ATT CTC CAA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC
 A I V Q T L V N S V N S K I P

30 385 300 315
 AAG GCA TGC TGT GTC CCA ACA GAG CTC AGC GCC ATC TCC ATG CTG
 K A C C V P T E L S A I S M L

35 330 345 360
 TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC
 Y L D E N E K V V L K N Y O D

40 375 (129) 397 407
 ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAAAATA
M V V E G C G C R

45 417 427 437 447 457
 TAAATATATA TATATATATA TTAGAAAAAC AGCAAAAAAA TCAAGTTGAC

50 467 477 487 497 507
 ACTTTAATAT TTCCAATGA AGACTTTATT TATGGAATGG AATGGAGAAA

55 517 527 537 547 557
 AAGAAAAACA CAGCTATTTT GAAAACATA TTTATATCTA CCGAAAAGAA

567 577 587
 GTTGGGAAAA CAAATATTTT AATCAGAGAA TTATT,

50 wherein said process comprises the following steps:

- a) screening a gene library constructed from bovine liver DNA or cDNA with a labelled probe designed on the basis of the amino acid sequence of a fragment of bBMP-2,
 - b) isolating positive clones, and
 - c) isolating the DNA-inserts from said clones.
7. The process according to claim 6, wherein the gene encodes bovine BMP-2 having the amino acid sequence of claim 6.

8. A process for the preparation of a gene encoding a protein exhibiting properties of bovine BMP-2 and comprising DNA sequences:

- 5 a) which differ from a DNA sequence of claim 7 in codon sequence due to the degeneracy of the genetic code;
b) which hybridize with a DNA sequence of claim 7 or section a), above; or
c) represent fragments, allelic or other variations of a DNA sequence of claim 7, whether said variations result in changes in the peptide sequence or not,

10 wherein said process comprises standard techniques of molecular biology.

11. The process according to claim 8, wherein the DNA sequence is a genomic DNA sequence.

12. The process according to claim 8, wherein the DNA sequence is a cDNA sequence.

13. 11. A process for the preparation of a gene encoding human BMP-4 comprising the following DNA sequence:

20

25

30

35

40

45

50

55

10 20 30 40 50 60 70
 CICTAGAGGG CAGAGGGAGGA GGGAGGGAGG GAAGGGAGCC GGAGGCGGGC COGGAAGCTA GGTGAGTG
 5
 80 90 100 110 120 130 140
 GCATCGAGC TGAGGGAGC GAGCGTGAAGA CGCGCGCTGT GCTCGGGCTG ACTATCTAGC TTGTCCTCCCC
 10
 150 160 170 180 190 200 210
 GATGGGATTG COGTOCAAGC TATCTGAGC CTGCAGCGCC ACAGTCCCCG GCGCTCGGCC AGGTTACCTG
 15
 220 230 240 250 260 270 280
 CAACCGTTCA GAGGTOOCCA GGAGCTGCTG CTGGCGAGCC CGCTACTGCA GGGACCTATG GACOCATTCC
 20
 290 300 310 320 330 340 350
 GTAGTGCCTAT CGCGAGCAAC GCACTGCTGC AGCTTCCCTG AGCCTTTCCA GCAAGTTTGT TCAAGATTTG
 360 370 380 390 400 (1)
 CIGTCAAGAA TCATGGACTG TTTTTATATG CCTCTTTTC TGTCAAGACA CC ATG ATT CCT
 MET Ile Pro...
 25
 417 432 447 462
 GGT AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA GGA GCC GCG
 Gly Asn Arg MET Leu MET Val Val Leu Leu Cys Gln Val Leu Leu Gly Gly Ala
 30
 477 492 507
 AGC CAT GCT AGT TTG ATA CCT GAG ACG CGG AAG AAA AAA GTC GGC GAG ATT CAG
 Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Val Ala Glu Ile Gln
 35
 522 537 552 567
 GGC CAC GCG GGA GGA CGC CGC TCA GGG CAG AGC CAT GAG CTC CTG CGG GAC TTC
 Gly His Ala Gly Arg Arg Ser Gly Gln Ser His Glu Leu Leu Arg Asp Phe
 40
 582 597 612 627
 GAG GCG ACA CTT CTG CAG ATG TTT GGG CTG CGC CGC CGC CAG OCT AGC AAG
 Glu Ala Thr Leu Leu Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys
 45
 642 657 672
 AGT GCG GTC ATT CGG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT GGG GAG
 Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu
 50
 687 702 717 732
 GAG GAG GAA GAG CAG ATC CAC AGC ACT GGT CTT GAG TAT CCT GAG GGC CGC GCG
 Glu Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala

747 762 777

AGC CGG GCC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC
Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile

5 792 807 822 837

CCA CGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC
Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile

10 852 867 882 897

CCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TTC CGG GAG CAG GTG
Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val

15 912 927 942

GAC CAG CGC OCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT TAT GAG GTT
Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val

20 957 972 987 1002

ATG AAG CCG CCA GCA GAA GTG GTG OCT CGG CAC CTC ATC ACA CGA CTA CTG GAC
MET Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp

25 1017 1032 1047

ACG AGA CTG GTC CAC CAC AAT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC OCT
Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro

30 1062 1077 1092 1107

GCG GTC CTT CGC TGG ACC CGG GAG AAG CAG CCA AAC TAT GGG CTA GCG ATT GAG
Ala Val Leu Arg Trp Thr Arg Glu Lys Gln Pro Asn Tyr Gly Leu Ala Ile Glu

35 1122 1137 1152 1167

GTG ACT CAC CTC CAT CAG ACT CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT AGC
Val Thr His Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser

40 1182 1197 1212

CGA TCG TTA CCT CAA GGG AGT GGG AAT TGG CCC CAG CTC CGG CCC CTC CTG GTC
Arg Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu Val

45 1227 1242 1257 1272

ACC TTT GGC CAT GAT GGC CGG GGC CAT GCC TTG ACC CGA CGC CGG AGG GCC AAG
Thr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg Ala Lys

50 1287 1302 1317

CGT AGC CCT AAG CAT CAC TCA CAG CGG GGC AGG AAG AAG AAT AAG AAC TGC CGG
Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg

55 1332 1347 1362 1377

CGC CAC TCG CTC TAT GTG GAC TTC ACC GAT GTG GGC TGG AAT GAC TGG ATT GTG
Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val

59 1392 1407 1422 1437

GCC CCA CCA GGC TAC CAG GGC TTC TAC TGC CAT GGG GAC TGC CCC TTT CCA CTG
Ala Pro Pro Glv Tvr Gln Ala Phe Tvr Cvs His Glv Asn Cvs Pro Phe Pro Leu

55 1452 1467 1482

GCT GAC CAC CTC AAC TCA ACC AAC CAT GCC ATT GTG CAG ACC CTG GTC AAT TCT
Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser

1497 1512 1527 1542

GTC AAT TCC AGT ATC CCC AAA GGC TGT TGT GTG CCC ACT GAA CTG AGT GCC ATC
Val Asn Ser Ser Ile Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile

5 1557 1572 1587

TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG GTG GTA CTG AAA AAT TAT CAG GAG
Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu

10 1602 1617 (408) 1636 1646 1656

ATG GTA GTA GAG GGA TGT CGG TGC CGC TGAGATCAGG CAGTCCTTGA GGATAGACAG
MET Val Val Glu Gly Cys Gly Cys Arg

15 1666 1676 1686 1696 1706 1716 1726

ATATACACAC CACACACACA CACCACATAC ACCACACACA CAOGTTCCA TOCACTCAAC CACACACTAC

20 1736 1746 1756 1766 1776 1786 1796

ACAGACTGCT TCTTATAGC TGGACTTTA TTAAAAAAA AAAAAAAA AATGGAAAAA ATOOCTAAC

25 1806 1816 1826 1836 1846 1856 1866

ATTCACTTG ACCTTATTAA TGACTTTACG TGCAATGTT TTGACCATAT TGATCATATA TTTTGACAAA

30 1876 1886 1896 1906 1916 1926 1936

ATATATTAT AACTACGTAT TAAAAGAAAA AAATAAAATG AGTCATTATT TTAAAAAAA AAAAAAAACT

35 1946
CTAGAGTOGA CGGAATTC ,

wherein said process comprises the following steps:

- 35 a) screening of a gene library constructed from U-2 OS derived DNA or cDNA with a labelled bBMP-2 fragment by hybridization,
b) isolating positive clones, and
c) isolating the DNA-inserts from said clones.
- 40 12. The process according to claim 11, wherein the gene encodes human BMP-4 having the amino acid sequence given in claim 11.
- 45 13. A process for the preparation of a gene encoding a protein exhibiting properties of BMP-4 and comprising a DNA sequence:

- 50 a) which differs from a DNA sequence of claim 11 in codon sequence due to the degeneracy of the genetic code;
b) which hybridizes with DNA sequence of claim 11 or section a), above; or
c) represents a fragment, allelic or other variation of a DNA sequence of claim 11, whether said variation results in changes in the peptide sequence or not,
- 55 wherein said process comprises standard techniques of molecular biology.
14. The process according to claim 13, wherein the DNA sequence is a genomic DNA sequence.
- 55 15. The process according to claim 13, wherein the DNA sequence is a cDNA sequence.
16. A vector containing the gene or DNA sequence prepared according to any one of claims 1 to 15 in operative association with an expression control sequence.

17. A cell transformed with a vector of claim 16.
18. The cell of claim 17 which is a mammalian cell, a bacterial cell, an insect cell or a yeast cell.
- 5 19. The cell of claim 18 which is a CHO cell.
- 10 20. A process for the preparation of a protein exhibiting properties of BMP-2, wherein said process comprises the steps of culturing in a suitable culture medium a cell transformed with an expression vector comprising a gene or a DNA sequence prepared according to any one of claims 1 to 10, and recovering said protein from said culture medium.
- 15 21. A process for the preparation of a protein exhibiting properties of BMP-4, wherein said process comprises the steps of culturing in a suitable culture medium a cell transformed with an expression vector comprising a gene or a DNA sequence prepared according to any one of claims 11 to 15, and recovering said protein from said culture medium.
- 20 22. A process for producing a protein exhibiting properties of BMP-2 or BMP-4, comprising the steps of culturing in a suitable culture medium the cell of claim 17 and isolating said protein from said culture medium.
- 25 23. A process for the preparation of a pharmaceutical composition comprising combining the proteins prepared according to any one of claims 20 to 22, individually or in combination with a pharmaceutically acceptable vehicle.
24. The process according to claim 23, wherein said pharmaceutical composition further comprises a matrix capable of delivering the composition to the site of the bone or cartilage defect and providing a structure for inducing bone or cartilage formation.
- 30 25. The process according to claim 24, wherein said matrix comprises hydroxyapatite, collagen, polylactic acid or tricalcium phosphate.
26. Use of a protein prepared according to any one of claims 20 to 22, individually or in combination, for the preparation of a pharmaceutical composition for inducing bone or cartilage formation.

Patentansprüche

35

Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

40
1. Menschliches BMP-2 codierendes Gen, umfassend die nachfolgende DNA-Sequenz:

45

50

55

	10	20	30	40	50
	GTCGACTCTA GAGTGTGTGT CAGCACTTGG CTGGGGACTT CTTGAACCTG				
5	60	70	80	90	100
	CAGGGAGAAT AACTTGCGCA CCCCACCTTG CGCCGGTGCC TTTGCCCGAG				
	110	120	130	140	150
	CGGAGCCTGC TTCGCCATCT CCGAGCCCCA CCGCCCCCTCC ACTCCTCGGC				
10	160	170	180	190	200
	CTTGCCCCGAC ACTGAGACGC TGTTCCCAGC GTGAAAAGAG AGACTGCGCG				
15	210	220	230	240	250
	GCCGGCACCC GGGAGAAGGA GGAGGCAAAG AAAAGGAACG GACATTGGT				
	260	270	280	290	300
	CCTTGCGCCA GGTCCCTTGA CCAGAGTTTT TCCATGTGGA CGCTCTTCA				
20	310	320	330	340	350
	ATGGACGTGT CCCCGCGTGC TTCTTAGACG GACTGCGGTC TCCTAAAGGT				
	(1)	370	385	400	
25	CGAOC ATG GTG GCC GGG ACC CGC TGT CTT CTA GCG TIG CTG CTT CCC CAG GTC MET Val Ala Gly Thr Arg Cys Leu Leu Leu Leu Pro Gln Val				
	415	430	445		
30	CTC CTG GGC GGC GCG GCT GGC CTC GTT CCC GAG CTG GGC CGC AGG AAG TTC GCG Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala				
	460	475	490	505	
	GCG GCG TCG TCG GGC CGC CCC TCA TCC CAG CCC TCT GAC GAG GTC CTG AGC GAG Ala Ala Ser Ser Gly Arg Pro Ser Ser Gln Pro Ser Asp Glu Val Leu Ser Glu				
35	520	535	550	565	
	TTC GAG TTG CGG CTG CTC AGC ATG TTC GGC CTG AAA CAG AGA CCC ACC CCC AGC Phe Glu Leu Arg Leu Leu Ser MET Phe Gly Leu Lys Gln Arg Pro Thr Pro Ser				
40	580	595	610		
	AGG GAC GGC GTG GTG CCC CCC TAC ATG CTA GAC CTG TAT CGC AGG CAC TCG GGT Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly				

45

50

55

625 640 655 670
 CAG CGG GGC TCA CCC GCC CCA GAC CAC CGG TTG GAG AGG GCA GCC AGC CGA GCC
 5 Gln Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala

 685 700 715
 AAC ACT GTG CGC AGC TTC CAC CAT GAA GAA TCT TTG GAA GAA CTA CCA GAA ACG
 10 Asn Thr Val Arg Ser Phe His His Glu Ser Leu Glu Glu Leu Pro Glu Thr

 730 745 760 775
 AGT GGG AAA ACA AOC CGG AGA TTC TTC TTT ATT TTA AGT TCT ATC CCC ACG GAG
 15 Ser Gly Lys Thr Thr Arg Arg Phe Phe Asn Leu Ser Ser Ile Pro Thr Glu

 790 805 820 835
 GAG TTT ATC ACC TCA GCA GAG CTT CAG GTG TTC CGA GAA CAG ATG CAA GAT GCT
 Glu Phe Ile Thr Ser Ala Glu Leu Gln Val Phe Arg Glu Gln MET Gln Asp Ala

 850 865 880
 TTA GGA AAC AAT AGC AGT TTC CAT CAC CGA ATT ATT ATT TAT GAA ATC ATA AAA
 20 Leu Gly Asn Asn Ser Ser Phe His His Arg Ile Asn Ile Tyr Glu Ile Ile Lys

 895 910 925 940
 CCT GCA ACA GCC AAC TCG AAA TTC CCC GTG ACC AGT CTT TTG GAC ACC AGG TTG
 25 Pro Ala Thr Ala Asn Ser Ilys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Leu

 955 970 985
 GTG AAT CAG AAT GCA AGC AGG TGG GAA AGT TTT GAT GTC ACC CCC GCT GTG ATG
 30 Val Asn Gln Asn Ala Ser Arg Trp Glu Ser Phe Asp Val Thr Pro Ala Val MET

 1000 1015 1030 1045
 CCG TGG ACT GCA CAG CGA CAC GGC AAC CAT GGA TTC GTG GTG GAA GTG GGC CAC
 35 Arg Trp Thr Ala Gln Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His

 1060 1075 1090 1105
 TTG GAG GAG AAA CAA GGT GTC TCC AAG AGA CAT GTT AGG ATA AGC AGG TCT TTG
 Leu Glu Glu Lys Gln Gly Val Ser Lys Arg His Val Arg Ile Ser Arg Ser Leu

 1120 1135 1150
 CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTA GTA ACT TTT GGC
 His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu Val Thr Phe Gly

 1165 1180 1195 1210
 45 CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GGC AAA CAC
 His Asp Gly Lys Gly His Pro Leu His Lys Arg Glu Lys Arg Gln Ala Lys His

 1225 1240 1255
 50 AAA CAG CGG AAA CGC CCT AAG TCC AGC TGT AAG AGA CAC CCT TTG TAC GTG GAC
 Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp

 1270 1285 1300 1315
 TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT GTG GCT CCC CGG GGG TAT CAC GCC
 Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala

1330 1345 1360 1375
 TTT TAC TGC CAC GGA GAA TGC OCT TTT CCT CTG GCT GAT CAT CTG AAC TCC ACT
 Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr

5 1390 1405 1420
 ATT CAT GGC ATT GTT CAG ACG TTG GTC AAC TCT GTC AAC TCT AAG ATT CCT AAG
 Asn His Ala Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys

10 1435 1450 1465 1480
 GCA TGC TGT GTC CGG ACA GAA CTC AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG
 Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser MET Leu Tyr Leu Asp Glu

15 1495 1510 1525
 AAT GAA AAG GTT GTA TTA AAG AAC TAT CAG GAC ATG GTT GTG GAG GGT TGT GGG
 Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp MET Val Val Glu Gly Cys Gly

20 1540(396) 1553 1563 1573 1583 1593 1603
 TGT CGC TAGTACAGCA AAAATTAAATA CATAAATATA TATATATATA TATATTTAG AAAAAAGAAA
 Cys Arg

25 **AAAA**

2. Gen, das menschliches BMP-2 codiert, das die in Anspruch 1 angegebene Aminosäuresequenz aufweist.
3. Gen, das ein Protein codiert, das Eigenschaften von menschlichem BMP-2 zeigt, und eine DNA-Sequenz umfaßt, die:
 - (a) sich in der Codonsequenz infolge der Degeneriertheit des genetischen Codes von einer DNA-Sequenz nach Anspruch 1 unterscheidet;
 - (b) mit einer DNA-Sequenz nach Anspruch 1 oder nach vorstehendem Absatz (a) hybridisiert; oder
 - (c) ein Fragment, eine allelische oder eine andere Variation einer DNA-Sequenz nach Anspruch 1 darstellt, unabhängig davon, ob die Variation zu Änderungen in der Peptidsequenz führt oder nicht.
4. DNA-Sequenz nach Anspruch 3, dadurch gekennzeichnet, daß sie eine genomische DNA-Sequenz ist.
- 40 5. DNA-Sequenz nach Anspruch 3, dadurch gekennzeichnet, daß sie eine cDNA-Sequenz ist.
6. Rinder-BMP-2 codierendes Gen, umfassend die nachfolgende DNA-Sequenz:

45

50

55

5	(1) 15 GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG G H D G K G H P L H R R E K R	30 30	45
10	60 CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG Q A K H K Q R K R L X S S C K	75 75	90
15	105 AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC R H P L Y V D F S D V G W N D	120 120	135
20	150 TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG W I V A P P G Y H A F Y C H G	165 165	180
25	195 GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT E C P F P L A D H L N S T N H	210 210	225
30	240 GCC ATT CTC CAA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC A I V Q T L V N S V N S K I P	255 255	270
35	385 AAG GCA TGC TGT GTC CCA ACA GAG CTC AGC GCC ATC TCC ATG CTG K A C C V P T E L S A I S M L	300 300	315
40	330 TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC Y L D E N E K V V L K N Y Q D	345 345	360
45	375 ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAAATA	(129) 397	407

40	417	427	437	447	457
	TAAAATATATA	TATATATATA	TTAGAAAAAAAC	AGCAAAAAAA	TCAAGTTGAC
45	467	477	487	497	507
	ACTTTTAATAT	TTCCCCAATGA	AGACTTTTATT	TATGGAAATGG	AATGGAGAGAA
50	517	527	537	547	557
	AAAGAIIIAACA	CAGCTATTTT	CAAACTATA	TTTATATCTA	CCCGAIIANGAA
	567	577	587		
	GTTGGGGAAA	CAAAATATTTT	AATCAGAGAGAA	TTATT	/

7. Gen, das Rinder-BMP-2 codiert, das die Aminosäuresequenz von Anspruch 6 enthält.

55 8. Gen, das ein Protein codiert, das Eigenschaften von Rinder-BMP-2 zeigt, und DNA-Sequenzen umfaßt, die:
(a) sich in der Codonsequenz infolge der Degeneriertheit des genetischen Codes von einer DNA-Sequenz nach Anspruch 7 unterscheiden;

- (b) mit einer DNA-Sequenz nach Anspruch 7 oder nach vorstehendem Absatz (a) hybridisieren; oder
(c) Fragmente, allelische oder andere Variationen einer DNA-Sequenz nach Anspruch 7 darstellen, unabhängig davon, ob die Variationen zu Änderungen in der Peptidsequenz führen oder nicht.

5

9. DNA-Sequenz nach Anspruch 8, dadurch gekennzeichnet, daß sie eine genomische DNA-Sequenz ist.
10. DNA-Sequenz nach Anspruch 8, dadurch gekennzeichnet, daß sie eine cDNA-Sequenz ist.
10 11. Menschliches BMP-4 codierendes Gen, umfassend die nachfolgende DNA-Sequenz:

10 20 30 40 50
CTCTAGAGGG CAGAGGAGGA GGGAGGGAGG GAAGGAGCGC GGAGCCCGGC

15

20

25

30

35

40

45

50

55

60 70 80 90 100
 CCGGAAGCTA GGTGAGTGTG GCATCCGAGC TGAGGGACGC GAGCCTGAGA

5 110 120 130 140 150
 CGCCGCTGCT GCTCCGGCTG AGTATCTAGC TTGTCTCCCC GATGGGATTG

10 160 170 180 190 200
 CCGTCCAAGC TATCTCGAGC CTGCAGCGCC ACAGTCCCCG GCCCTCGCCC

15 210 220 230 240 250
 AGGTTCACTG CAACCGTTCA GAGGTCCCCA GGAGCTGCTG CTGGCGAGCC

20 260 270 280 290 300
 CGCTACTGCA GGGACCTATG GAGCCATTCC GTAGTGCCAT CCCGAGCAAC

25 310 320 330 340 350
 GCACTGCTGC AGCTTCCCTG AGCCTTTCCA GCAAGTTTGT TCAAGATTGG

30 360 370 380 390 400
 CTGTCAAGAA TCATGGACTG TTATTATATG CCTTGTTTTC TGTCAAGACA

(1)
 CC ATG ATT CCT
 25 MET Ile Pro

417 432 447 462
 GGT AAC CGA ATG CTG ATG GTC GTC TTA TTA TGC CAA GTC CTG CTA GGA GGC GCG
 30 Gly Asn Arg MET Leu MET Val Val Leu Leu Cys Gln Val Leu Leu Gly Ala

477 492 507
 AGC CAT GCT AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GGC GAG ATT CAG
 Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Val Ala Glu Ile Gln

522 537 552 567
 GGC CAC GCG CGA CGA CGC CGC TCA CGG CAG AGC CAT GAG CTC CTG CGG GAC TTC
 Gly His Ala Gly Arg Arg Ser Gly Gln Ser His Glu Leu Leu Arg Asp Phe

582 597 612 627
 GAG GCG ACA CTT CTG CAG ATG TTT CGG CTC CGC CGC CGG CAG CCT AGC AAG
 40 Glu Ala Thr Leu Leu Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys

642 657 672
 AGT GGC GTC ATT CGG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT GGG GAG
 45 Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu

687 702 717 732
 GAG GAG GAA GAG CAG ATC CAC ACC ACT GGT CTT GAG TAT CCT GAG CGC CGG GCG
 Glu Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala

50 747 762 777
 AGC CGG GCC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC
 Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile

55

792 807 822 837
 CCT GGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC
 5 Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile

 852 867 882 897
 CCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CCT CCG CTC TTC CCG GAG CAG CTG
 10 Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val

 912 927 942
 GAC CAG CGC CCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT TAT GAG GTT
 Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val

 957 972 987 1002
 ATG AAG CCC CCA GCA GAA GTG GTG OCT GGG CAC CTC ATC ACA CGA CTA CTG GAC
 15 MET Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp

 1017 1032 1047
 ACG AGA CTG GTC CAC CAC AAT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCT
 Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro

 1062 1077 1092 1107
 GCG GTC CTT CGC TGG ACC CGG GAG AAG CAG CCA AAC TAT GGG CTA GGC ATT GAG
 20 Ala Val Leu Arg Trp Thr Arg Glu Lys Gln Pro Asn Tyr Gly Leu Ala Ile Glu

 1122 1137 1152 1167
 GTG ACT CAC CTC CAT CGC ACT CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT AGC
 25 Val Thr His Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser

 1182 1197 1212
 CGA TCG TTA CCT CAA GGG AGT GGG AAT TGG GCC CAG CTC CCG COC CTC CTG GTC
 Arg Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu Val

 1227 1242 1257 1272
 ACC TTT GGC CAT GAT GGC CGG CCC CAT GCC TTG ACC CGA CGC CGG AGG GCC AAG
 30 Thr Phe Gly His Asp Gly Arg His Ala Leu Thr Arg Arg Arg Arg Ala Lys

 1287 1302 1317
 CGT AGC CCT AAG CAT CAC TCA CAG CGG GCC AGG AAG AAG AAT AAG AAC TGC CGG
 35 Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg

 1332 1347 1362 1377
 CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC TGG ATT GTG
 40 Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val

 1392 1407 1422 1437
 GCC CCA CCA CGC TAC CAG GCC TTC TAC TGC CAT GGG GAC TGC CCC TTT CCA CTG
 Ala Pro Pro Glv Tyr Gln Ala Phe Tyr Cys His Glv Asn Cys Pro Phe Pro Leu

 45 1452 1467 1482
 GCT GAC CAC CTC AAC TCA ACC AAC CAT GGC ATT GTG CAG ACC CTG GTC ATT TCT
 Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser

1497 1512 1527 1542
 GTC AAT TCC AGT ATC CCC AAA GGC TGT TGT GTG CCG ACT GAA CTG AGT GGC ATC
 Val Asn Ser Ser Ile Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile

5 1557 1572 1587
 TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG GTG GTA CTG AAA AAT TAT CAG GAG
 Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu

10 1602 1617 (408) 1636 1646 1656
 ATG GTC GTC GAG GGA TGT GGG TGC CGC TGAGATCAGG CAGTCCTTGA CGATAGACAG
 MET Val Val Glu Gly Cys Gly Cys Arg

15
 1666 1676 1686 1696 1706
 ATATAACACAC CACACACACA CACCACATAC ACCACACACA CACGTTCCCA

20 1716 1726 1736 1746 1756
 TCCACTCACC CACACACTAC ACAGACTGCT TCCTTATAGC TGGACTTTA

25 1766 1776 1786 1796 1806
 TTTAAAAAAA AAAAAAAA AATGGAAAAA ATCCCTAAC ATTACACCTTG

30 1816 1826 1836 1846 1856
 ACCTTATTAA TGACTTTACG TGCAAATGTT TTGACCATAT TGATCATATA

35 1866 1876 1886 1896 1906
 TTTTGACAAA ATATATTTAT AACTACGTAT TAAAAGAAAA AAATAAAATG

40 1916 1926 1936 1946
 AGTCATTATT TTAAAAAAA AAAAAAAACT CTAGAGTCGA CGGAATTC

- 35 12. Gen, das menschliches BMP-4 codiert, das die in Anspruch 11 angegebene Aminosäuresequenz aufweist.
- 40 13. Gen, das ein Protein codiert, das Eigenschaften von BMP-4 zeigt, und eine DNA-Sequenz umfaßt, die:
- (a) sich in der Codonsequenz infolge der Degeneriertheit des genetischen Codes von einer DNA-Sequenz nach Anspruch 11 unterscheidet;
 - (b) mit einer DNA-Sequenz nach Anspruch 11 oder nach vorstehendem Absatz (a) hybridisiert; oder
 - (c) ein Fragment, eine allelische oder eine andere Variation einer DNA-Sequenz nach Anspruch 11 darstellt, unabhängig davon, ob die Variation zu Änderungen in der Peptidsequenz führt oder nicht.
- 45 14. DNA-Sequenz nach Anspruch 13, dadurch gekennzeichnet, daß sie eine genomische DNA-Sequenz ist.
- 50 15. DNA-Sequenz nach Anspruch 13, dadurch gekennzeichnet, daß sie eine cDNA-Sequenz ist.
- 55 16. Vektor, enthaltend das Gen oder die DNA-Sequenz nach einem der Ansprüche 1 bis 15 in einer funktionellen Verbindung mit einer Expressions-Kontrollsequenz.
- 60 17. Zelle, dadurch gekennzeichnet, daß sie mit einem Vektor nach Anspruch 16 transformiert ist.
- 65 18. Zelle nach Anspruch 17, dadurch gekennzeichnet, daß sie eine Säugerzelle, eine Bakterienzelle, eine Insektenzelle oder eine Hefezelle ist.

19. Zelle nach Anspruch 18, dadurch gekennzeichnet, daß sie eine CHO-Zelle ist.
20. Protein, das Eigenschaften von BMP-2 aufweist, das durch ein Gen oder eine DNA-Sequenz nach einem der Ansprüche 1 bis 10 codiert ist.
- 5 21. Protein, das Eigenschaften von BMP-2 aufweist, das erhältlich ist durch die Schritte
- Züchten einer mit einem Expressionsvektor transformierten Zelle in einem geeigneten Kulturmedium, wobei der Vektor ein Gen oder eine DNA-Sequenz nach einem der Ansprüche 1 bis 10 umfaßt, und
- 10 - Gewinnen des Proteins aus dem Kulturmedium.
22. Protein, das Eigenschaften von BMP-4 aufweist, das durch ein Gen oder eine DNA-Sequenz nach einem der Ansprüche 11 bis 15 codiert ist.
- 15 23. Protein, das Eigenschaften von BMP-4 aufweist, das erhältlich ist durch die Schritte
- Züchten einer mit einem Expressionsvektor transformierten Zelle in einem geeigneten Kulturmedium, wobei der Vektor ein Gen oder eine DNA-Sequenz nach einem der Ansprüche 11 bis 15 umfaßt und
- 20 - Isolieren des Proteins aus dem Kulturmedium.
24. Verfahren zur Herstellung des Proteins nach Anspruch 21 oder 23, umfassend die Schritte
- 25 - Züchten der Zelle nach Anspruch 17 in einem geeigneten Kulturmedium und
- Gewinnen des Proteins aus dem Kulturmedium.
26. Arzneimittel, dadurch gekennzeichnet, daß es, einzeln oder in Kombination, die Proteine nach einem der Ansprüche 20 bis 23 und einen pharmakologisch verträglichen Träger umfaßt.
- 30 27. Arzneimittel nach Anspruch 25, dadurch gekennzeichnet, daß es ferner eine Matrix umfaßt, die fähig ist, das Arzneimittel an die Stelle des Knochen- oder Knorpelschadens zu liefern und eine Struktur zur Induktion der Knochen- oder Knorpelbildung bereitzustellen.
- 35 28. Arzneimittel nach Anspruch 26, dadurch gekennzeichnet, daß die Matrix Hydroxyapatit, Kollagen, Polyessigsäure oder Tricalciumphosphat umfaßt.
- 40 29. Verwendung des Proteins nach einem der Ansprüche 20 bis 23, einzeln oder in Kombination, zur Herstellung eines Arzneimittels zur Induktion der Knochen- oder Knorpelbildung.

Patentansprüche für folgenden Vertragsstaat : AT

- 45 1. Verfahren zur Herstellung eines menschlichen BMP-2 codierenden Gens, das die nachfolgende DNA-Sequenz umfaßt:

50

55

10 20 30 40 50
 GTCGACTCTA GAGTGTGTGT CAGCACTTGG CTGGGGACTT CTTGAACCTG

5 60 70 80 90 100
 CAGGGAGAAAT AACTTGCGCA CCCCCACTTTG CGCCGGTGCC TTTGCCCGAG

10 110 120 130 140 150
 CGGAGCCTGC TTCGCCATCT CCGAGCCCCA CCGCCCCCTCC ACTCCTCGGC

15 160 170 180 190 200
 CTTGCCCGAC ACTGAGACGC TGTTCCCAGC GTGAAAAGAG AGACTGCGCG

15 210 220 230 240 250
 GCCGGCACCC GGGAGAAGGA GGAGGCAAAG AAAAGGAACG GACATTGGT

20 260 270 280 290 300
 CCTTGCGCCA GGTCCCTTTGA CCAGAGTTTT TCCATGTGGA CGCTCTTTCA

20 310 320 330 340 350
 ATGGACGTGT CCCCGCGTGC TTCTTAGACG GACTGCGGTC TCCTAAAGGT

25 (1) 370 385 400
 CGACC ATG GTG CCC GGG AOC CGC TGT CTT CTA GCG TIG CTG CTT CCC CAG GTC
 MET Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Leu Pro Gln Val

30 415 430 445
 CTC CTG GGC GGC GCG GCT GGC CTC GTT CCG GAG CTG GGC CGC AGG AAG TTC GCG
 Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala

460 475 490 505
 GCG GCG TCG TCG GGC CGC OOC TCA TOC CAG OOC TCT GAC GAG GTC CTG ACC GAG
 Ala Ala Ser Ser Gly Arg Pro Ser Ser Gln Pro Ser Asp Glu Val Leu Ser Glu

35 520 535 550 565
 TTC GAG TTG CGG CTG CTC AGC ATG TTC GGC CTG AAA CAG AGA CCC ACC ACC CGC
 Phe Glu Leu Arg Leu Leu Ser MET Phe Gly Leu Lys Gln Arg Pro Thr Pro Ser

40 580 595 610
 AGG GAC GGC GTG GTG CCC OOC TAC ATG CTA GAC CTG TAT CGC AGG CRC TCG GGT
 Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly

45

50

55

625 640 655 670

CAG CCG GGC TCA CCC GOC CCA GAC CAC CGG TTG GAG ACG GCA GCC AGC CGA GOC
Gln Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala

685 700 715

AAC ACT GTG CGC AGC TTC CAC CTT GAA GAA TCT TTG GAA GAA CTC CCA GAA ACG
Asn Thr Val Arg Ser Phe His His Glu Glu Ser Leu Glu Glu Leu Pro Glu Thr

730 745 760 775

AGT GGG AAA ACA AAC CGG AGA TTC TTC TTT ATT TTA AGT TCT ATC CCC ACG GAG
Ser Gly Lys Thr Thr Arg Arg Phe Phe Asn Leu Ser Ser Ile Pro Thr Glu

790 805 820 835

GAG TTT ATC ACC TCA GCA GAG CTT CAG GTT TTG CGA GAA CAG ATG CAA GAT GCT
Glu Phe Ile Thr Ser Ala Glu Leu Gln Val Phe Arg Glu Gln MET Gln Asp Ala

850 865 880

TTA GGA AAC ATT AGC AGT TTC CAT CAC CGA ATT ATT ATT TAT GAA ATC ATA AAA
Leu Gly Asn Asn Ser Ser Phe His His Arg Ile Asn Ile Tyr Glu Ile Ile Lys

895 910 925 940

CCT GCA ACA GCA AAC TCG AAA TTC CCC GIG ACC AGT CTC TTG GAC ACC AGG TTG
Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Leu

955 970 985

GTG ATT CAG ATT GCA AGC AGG TGG GAA AGT TTT GAT GTC ACC OOC CCT GIG ATG
Val Asn Gln Asn Ala Ser Arg Trp Glu Ser Phe Asp Val Thr Pro Ala Val MET

1000 1015 1030 1045

CGG TGG ACT GCA CAG GGA CAC GCA AAC CAT GGA TTC GIG GIG GAA GIG GGC CAC
Arg Trp Thr Ala Gln Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His

1060 1075 1090 1105

TTG GAG GAG AAA CAA GGT GTC TOC AAG AGA CAT GTT AGG ATA AGC AGG TCT TTG
Leu Glu Glu Lys Gln Gly Val Ser Lys Arg His Val Arg Ile Ser Arg Ser Leu

1120 1135 1150

CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTC GTC ACT TTT GGC
His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu Val Thr Phe Gly

1165 1180 1195 1210

CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GGC AAA CAC
His Asp Gly Lys His Pro Leu His Lys Arg Glu Lys Arg Gln Ala Lys His

1225 1240 1255

AAA CAG CGG AAA CGC CCT AAG TOC AGC TGT AAG AGA CAC CCT TTG TAC GTG GAC
Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp

1270 1285 1300 1315

TTC AGT GAC GTG GGG TGG ATT GAC TGG ATT GTG CCT CCC CGG GGG TAT CAC GGC
Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala

1330 1345 1360 1375

TTT TAC TGC CAC GGA GAA TGC CCT TTT CCT CTG GCT GAT CTC AAC TCC ACT
Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr

1390 1405 1420

ATT CTC GCC ATT GTT CAG ACG TTG GTC AAC TCT GTT AAC TCT AAG ATT CCT AAG
Asn His Ala Ile Val Gln Tyr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys

1435 1450 1465 1480
 GCA TGC TGT GTC CCG ACA GAA CTC AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG
 Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser MET Leu Tyr Leu Asp Glu

5 1495 1510 1525
 AAT GAA AAG GTT GTA TTA AAG AAC TAT CAG GAC ATG GTT GTG GAG GGT TGT CGG
 Asn Glu Lys Val Val Lys Asn Tyr Gln Asp MET Val Val Glu Gly Cys Gly

10 1540(396) 1553 1563 1573 1583 1593 1603
 TGT CGC TAGTACAGCA AAATTAAATA CATAAATATA TATATATATA TATATTTAG AAAAAAGAAA
 Cys Arg

15 **AAAA,**

wobei das Verfahren die nachfolgenden Schritte umfaßt:

20 (a) Absuchen einer Genbank durch Hybridisieren mit einem markierten bBMP-2-Fragment, wobei die Genbank aus einer von U-2 OS abgeleiteten DNA oder cDNA konstruiert war,

(b) Isolieren positiver Clone und

(c) Isolieren der DNA-Insertionen aus diesen Clonen.

25 2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß das Gen menschliches BMP-2 codiert, das die in Anspruch 1 angegebene Aminosäuresequenz aufweist.

30 3. Verfahren zur Herstellung eines Gens, das ein Protein codiert, das Eigenschaften von menschlichem BMP-2 zeigt, und eine DNA-Sequenz umfaßt, die:

(a) sich in der Codonsequenz infolge der Degeneriertheit des genetischen Codes von einer DNA-Sequenz nach Anspruch 1 unterscheidet;

35 (b) mit einer DNA-Sequenz nach Anspruch 1 oder nach vorstehendem Absatz (a) hybridisiert; oder

(c) ein Fragment, eine allelische oder eine andere Variation einer DNA-Sequenz nach Anspruch 1 darstellt, unabhängig davon, ob die Variation zu Änderungen in der Peptidsequenz führt oder nicht,

40 wobei das Verfahren Standardtechniken der Molekularbiologie umfaßt.

4. Verfahren nach Anspruch 3, dadurch gekennzeichnet, daß die DNA-Sequenz eine genomische DNA-Sequenz ist.

5. Verfahren nach Anspruch 3, dadurch gekennzeichnet, daß die DNA-Sequenz eine cDNA-Sequenz ist.

45 6. Verfahren zur Herstellung eines Rinder-BMP-2 codierenden Gens, umfassend die nachfolgende DNA-Sequenz:

50

55

(1) 15 30 45
 GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG
 G H D G K G H P L H R R E K R

5 60 75 90
 CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG
 Q A K H K Q R K R L K S S C K

10 105 120 135
 AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC
 R H P L Y V D F S D V G W N D

15 150 165 180
 TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG
 W I V A P P G Y H A F Y C H G

20 195 210 225
 GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT
 E C P F P L A D H L N S T N H

25 240 255 270
 GCC ATT CTC CTA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC
 A I V Q T L V N S V N S K I P

30 385 300 315
 AAG GCA TGC TGT GTC CCA ACA GAG CTC AGC GCC ATC TCC ATG CTG
 K A C C V P T E L S A I S X L

35 330 345 360
 TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC
 Y L D E N E K V V L K N Y O D

375 (129) 397 407
 ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAAATA

40 417 427 437 447 457
 TAAATATATA TATATATATA TTAGAAAAAC AGCAAAAAAA TCAAGTTGAC

45 467 477 487 497 507
 ACTTTAATAT TTCCCAATGA AGACTTTATT TATGGAATGG AATGGAGAAA

50 517 527 537 547 557
 AAGAAAAACA CAGCTATTTT GAAAACATA TTTATATCTA CCGAAAAAGAA

567 577 587
 GTTGGGAAAA CAAATATTTT AATCAGAGAA TTATT

wobei das Verfahren die nachfolgenden Schritte umfaßt:

- 55 (a) Absuchen einer Genbank mit einer markierten auf der Grundlage der Aminosäuresequenz eines Fragments von bBMP-2 entworfenen Sonde, wobei die Genbank aus Rinderleber-DNA oder cDNA konstruiert wurde,
- (b) Isolieren positiver Clone und

(c) Isolieren der DNA-Insertionen aus diesen Clonen.

7. Verfahren nach Anspruch 6, dadurch gekennzeichnet, daß das Gen Rinder-BMP-2 codiert, das die Aminosäuresequenz von Anspruch 6 aufweist.

5 8. Verfahren zur Herstellung eines Genes, das ein Protein codiert, das Eigenschaften von Rinder-BMP-2 zeigt, und DNA-Sequenzen umfaßt, die:

10 (a) sich in der Codonsequenz infolge der Degeneriertheit des genetischen Codes von einer DNA-Sequenz nach Anspruch 7 unterscheiden;

(b) mit einer DNA-Sequenz nach Anspruch 7 oder nach vorstehendem Absatz (a) hybridisieren; oder

15 (c) Fragmente, allelische oder andere Variationen einer DNA-Sequenz nach Anspruch 7 darstellen, unabhängig davon, ob die Variationen zu Änderungen in der Peptidsequenz führen oder nicht,

wobei das Verfahren Standardtechniken der Molekularbiologie umfaßt.

20 9. Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß die DNA-Sequenz eine genomische DNA-Sequenz ist.

10. Verfahren nach Anspruch 8, dadurch gekennzeichnet, daß die DNA-Sequenz eine cDNA-Sequenz ist.

11. Verfahren zur Herstellung eines menschlichen BMP-4 codierenden Genes, das die nachfolgende DNA-Sequenz umfaßt:

25	10	20	30	40	50
	CTCTAGAGGG	CAGAGGAGGA	GGGAGGGAGG	GAAGGAGCGC	GGAGCCCCGC
30	60	70	80	90	100
	CCGGAAGCTA	GGTGAGTGTG	GCATCCGAGC	TGAGGGACGC	GAGCCTGAGA
35	110	120	130	140	150
	CGCCGCTGCT	GCTCCGGCTG	AGTATCTAGC	TTGTCTCCCC	GATGGGATTC
40	160	170	180	190	200
	CCGTCCAAGC	TATCTCGAGC	CTGCAGCGCC	ACAGTCCCCG	GCCCTCGCCC
45	210	220	230	240	250
	AGGTTCACTG	CAACC GTTCA	GAGGTCCCCA	GGAGCTGCTG	CTGGCGAGCC
50	260	270	280	290	300
	CGCTACTGCA	GGGACCTATG	GAGCCATTCC	GTAGTGCCAT	CCCGAGCAAC
55	310	320	330	340	350
	GC ACTGCTGC	AGCTTCCCTG	AGCCTTCCA	GCAAGTTGT	TCAAGATTGG
	360	370	380	390	400
	CTGTCAAGAA	TCATGGACTG	TTATTATATG	CCTTGT TTTG	TGTCAAGACA

50

55

(1)
 CC ATG ATT CCT
 MET Ile Pro

5

	417	432	447	462	
	GGT AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA GGA GGC GCG				
	Gly Asn Arg MET Leu MET Val Val Leu Leu Cys Glu Val Leu Leu Gly Gly Ala				
10		477	492	507	
	AGC CAT GCT AGT TTG ATA CCT GAG ACG GGG AAG AAA AAA GTC GGC GCG AAT CAG				
	Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Lys Val Ala Glu Ile Gln				
15		522	537	552	567
	GGC CAC CGG GGA GGA CGC CGC TCA CGG CGG AGC CAT GAG CTC CTG CGG GAC TTC				
	Gly His Ala Gly Gly Arg Arg Ser Gly Gln Ser His Glu Leu Leu Arg Asp Phe				
20		582	597	612	627
	GAG CGG ACA CTT CTG CAG ATG TTT CGG CTG CGC CGC CGG CAG CCT AGC AAG				
	Glu Ala Thr Leu Leu Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys				
25		642	657	672	
	AGT GGC GTC ATT CGG GAC TAC ATG CGG GAT CTT TAC CGG CTT CGG CCT GGG GAG				
	Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu				
30		687	702	717	732
	GAG GAG GAA GAG CAG ATC CAC AGC ACT GGT CTT GAG TAT CCT GAG CGC CGG GGC				
	Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala				
35		747	762	777	
	AGC CGG GCC AAC ACC GTG AGG ACC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC				
	Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile				
40		792	807	822	837
	CCA GGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC				
	Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile				
45		852	867	882	897
	OCT GAG AAC GAG GTG ATC TCC TCT CGA GAG CTT CGG CTC TTC CGG GAG CAG GTG				
	Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val				
50		912	927	942	
	GAC CAG CGC CCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT TAT GAG GTT				
	Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val				
55		957	972	987	1002
	ATG AAG CCC CCA GCA GAA GTG GTG CCT CGG CAC CTC ATC ACA CGA CTC CTG GAC				
	MET Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp				
	1017	1032	1047		
	AGG AGA CTG GTC CGC CAC ATT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCT				
	Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro				
	1052	1077	1092	1107	
	CGG GTC CTT CGC TGG ACC CGG GAG AAG CAG CGA AAC TAT CGG CTC GGC ATT GAG				
	Ala Val Leu Arg Trp Thr Arg Glu Lys Gln Pro Asn Tyr Gly Leu Ala Ile Glu				

1122 1157 1152 1167
 GTG ACT CAC CTC CAT CGT ACT CGG ACC GAC CGG CCC CAG CAT GTC AGG ATT AGC
 Val Thr His Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser
 5
 1182 1197 1212
 CCA TCG TTA CCT CAA CGG AGT CGG AAT TGG GCC CAG CTC CGG CCC CTC CTG GTC
 Arg Ser Leu Pro Gln Gly Ser Gly Asn Thr Ala Gln Leu Arg Pro Leu Leu Val
 10 1227 1242 1257 1272
 ACC TTT GGC CAT GAT CGG CGG CGG CAT GCC TTG ACC CCA CGG CGG AGG CCC AAG
 Tyr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg Arg Ala Lys
 15 1287 1302 1317
 CGT AGC CCT AAG CAT CAC TCA CAG CGG GCC AGG AAG AAG AAT AAG AAC TGC CGG
 Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg
 20
 1332 1347 1362 1377
 CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC TGG ATT GTG
 Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Thr Asn Asp Thr Ile Val
 25
 1392 1407 1422 1437
 GGC CCA CCA CGC TAC CGG GCC TTC TAC TCC CAT CGG GAC TGC CGC TTT CCA CTG
 Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gln Asn Cys Pro Phe Pro Leu
 30 1452 1467 1482
 GCT GAC CAC CTC AAC TCA ACC AAC CAT GCG ATT GTG CAG ACC CTG GTC ATT TCT
 Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser
 35
 1497 1512 1527 1542
 GTC AAT TCC AGT ATC CCC AAA GCC TGT TGT GTG CCC ACT GAA CTG AGT GCC ATC
 Val Asn Ser Ser Ile Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile
 40
 1557 1572 1587
 TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG GTG GTC CTG AAA AAT TAT CGG GAG
 Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu
 45
 1602 1617 (408) 1636 1646 1656
 ATG GTC GTC GAG GGA TGT GCG TGC CGC TGAGATCAGG CAGTCCTGCA CGATGACAG
 MET Val Val Glu Gly Cys Gly Cys Arg
 50
 1666 1676 1686 1696 1706
 ATATAACACAC CACACACACA CACCACATAC ACCACACACA CACGTTCCCCA
 55 1716 1726 1736 1746 1756
 TCCACTCACC CACACACTAC ACAGACTGCT TCCTTATAGC TGGACTTTA
 1766 1776 1786 1796 1806
 TTTAAAAAAA AAAAAAAA AATGGAAAAAA ATCCCTAAC ATTACACCTTG

1816	1826	1836	1846	1856
ACCTTATTAA TGACTTTACG TGC AA ATGTT TTGACCATA T TGATCATATA				
5 1866	1876	1886	1896	1906
TTTGACAAA ATATATTAT AACTACGTAT TAAAAGAAAA AAATAAAATG				
10 1916	1926	1936	1946	
AGTCATTATT TTAAAAAAA AAAAAAAACT CTAGAGTCGA CGGAATTC				

wobei das Verfahren die nachfolgenden Schritte umfaßt:

- (a) Absuchen einer Genbank durch Hybridisieren mit einem markierten bBMP-2-Fragment, wobei die Genbank aus einer von U-2 OS abgeleiteten DNA oder cDNA konstruiert war,
 - (b) Isolieren positiver Clone und
 - (c) Isolieren der DNA-Insertionen aus diesen Clonen.
- 20 12. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß das Gen menschliches BMP-4 codiert, das die in Anspruch 11 angegebene Aminosäuresequenz aufweist.
13. Verfahren zur Herstellung eines Genes, das ein Protein codiert, das Eigenschaften von BMP-4 zeigt, und eine DNA-Sequenz umfaßt, die:
- (a) sich in der Codonsequenz infolge der Degeneriertheit des genetischen Codes von einer DNA-Sequenz nach Anspruch 11 unterscheidet;
 - (b) mit einer DNA-Sequenz nach Anspruch 11 oder vorstehendem Absatz (a) hybridisiert; oder
 - (c) ein Fragment, eine allelische oder eine andere Variation einer DNA-Sequenz nach Anspruch 11 darstellt, unabhängig davon, ob die Variation zu Änderungen in der Peptidsequenz führt oder nicht,
- wobei das Verfahren Standardtechniken der Molekularbiologie umfaßt.
- 35 14. Verfahren nach Anspruch 13, dadurch gekennzeichnet, daß die DNA-Sequenz eine genomische DNA-Sequenz ist.
15. Verfahren nach Anspruch 13, dadurch gekennzeichnet, daß die DNA-Sequenz eine cDNA-Sequenz ist.
- 40 16. Vektor, enthaltend das Gen oder die DNA-Sequenz nach einem der Ansprüche 1 bis 15 in einer funktionellen Verbindung mit einer Expressions-Kontrollsequenz.
17. Zelle, dadurch gekennzeichnet, daß sie mit einem Vektor nach Anspruch 16 transformiert ist.
- 45 18. Zelle nach Anspruch 17, dadurch gekennzeichnet, daß sie eine Säugerzelle, eine Bakterienzelle, eine Insektenzelle oder eine Hefezelle ist.
19. Zelle nach Anspruch 18, dadurch gekennzeichnet, daß sie eine CHO-Zelle ist.
- 50 20. Verfahren zur Herstellung eines Proteins, das Eigenschaften von BMP-2 zeigt, umfassend die Schritte
 - Züchten einer mit einem Expressionsvektor transformierten Zelle in einem geeigneten Kulturmedium, wobei der Expressionsvektor ein Gen oder eine DNA-Sequenz umfaßt, die nach einem der Ansprüche 1 bis 10 hergestellt wurden, und
 - Gewinnen des Proteins aus dem Kulturmedium.
- 55 21. Verfahren zur Herstellung eines Proteins, das Eigenschaften von BMP-4 zeigt, umfassend die Schritte

- Züchten einer mit einem Expressionsvektor transformierten Zelle in einem geeigneten Kulturmedium, wobei der Expressionsvektor ein Gen oder eine DNA-Sequenz umfaßt, die nach einem der Ansprüche 11 bis 15 hergestellt wurden, und

5 - Gewinnen des Proteins aus dem Kulturmedium.

22. Verfahren zur Herstellung eines Proteins, das Eigenschaften von BMP-2 oder BMP-4 zeigt, umfassend die Schritte

- Züchten der Zelle nach Anspruch 17 in einem geeigneten Kulturmedium und
- Isolieren des Proteins aus dem Kulturmedium.

10 23. Verfahren zur Herstellung eines Arzneimittels, dadurch gekennzeichnet, daß es ein Kombinieren der nach einem der Ansprüche 20 bis 22 hergestellten Proteine, einzeln oder in Kombination, mit einem pharmakologisch verträglichen Träger umfaßt.

15 24. Verfahren nach Anspruch 23, dadurch gekennzeichnet, daß das Arzneimittel ferner eine Matrix umfaßt, die fähig ist, das Arzneimittel an die Stelle des Knochen- oder Knorpelschadens zu liefern und eine Struktur zur Induktion der Knochen- oder Knorpelbildung bereitzustellen.

20 25. Verfahren nach Anspruch 24, dadurch gekennzeichnet, daß die Matrix Hydroxyapatit, Kollagen, Polyessigsäure oder Tricalciumphosphat umfaßt.

25 26. Verwendung eines Proteins nach einem der Ansprüche 20 bis 22, einzeln oder in Kombination, zur Herstellung eines Arzneimittels zur Induktion der Knochen- oder Knorpelbildung.

Revendications

30 **Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Gène codant pour la BMP-2 humaine comprenant la séquence d'ADN suivante :

35

40

45

50

55

10 20 30 40 50 60 70
 GTCGACTCTA CAGTGTGTGT CAGCACCTGG CTGGGGACAT CITGACATG CAGGGAGAT AACTTGCCCA
 5

80 90 100 110 120 130 140
 CCGCAGCTTG CGCGGGTGCC TTTCGCCCCAG CGGAGGCTGC TTAGGACATCT CGAGAGGGCGA CGGGGGCTCC

10 150 160 170 180 190 200 210
 ACTCTCTGGC CTTCGGGGAC ACTGAGAGGC TGTTCGGCAGC GTGAAAGAG AGACTGGGGC GCGGGGACCC

15 220 230 240 250 260 270 280
 GCGCGAGGA GGAGGCAAG AAAAGGAGAG GACATGGGT CCTTGCGCCA GGTCTTGA CGCGGTGTT

20 290 300 310 320 330 340 350
 TCCATGTTGA CGCTCTCA ATGGAGGCTG CGCGAGCTGC TTCTTGCG GACTGGGGTC TCCATGCT

(1) 370 385 400
 CGACCC ATG GTG GCC GGG ACC CGC TGT CTT CTA CGG TTG CTG CTT CCC CAG GTC
 MET Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Leu Ieu Pro Gln Val
 25

415 430 445
 CTC CTG CGC CGC CGG CCT CGC CTC GTT CGG CGC CTG CGC CGG AGG AAG TTC CGG
 Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala

30 450 475 490 505
 CGG CGG TCG TCG CGC CGC TCA TCC CGG CGC CCT CGC CGC CGC CGC AGC GAG
 Ala Ala Ser Ser Gly Arg Pro Ser Ser Gln Pro Ser Asp Glu Val Leu Ser Glu

35 520 535 550 565
 TTC GAG TTG CGG CTG CTC AGC ATG TTC CGC CTG AAA CGG AGA CGC ACC CGC AGC
 Phe Glu Leu Arg Leu Leu Ser MET Phe Gly Leu Lys Glu Arg Pro Thr Pro Ser

40 580 595 610
 AGG GAC GCG CGC CTG CGC CGC CGC ATG CTA GAC CTG TAT CGG AGG CGC CGC CGC CGT
 Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly

45 625 640 655 670
 CGG CGG CGC TCA CGC CGC CGA GAC CGC CGC CGG CGC CGC CGA CGC CGC CGC CGC
 Glu Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ala Ser Arg Ala

50 665 680 695 710
 AAC ACT GTG CGC AGC TTC CAC CAT GAA GAA TCT TTG GAA GAA CTA CGA GAA AGG
 Asn Thr Val Arg Ser Phe His His Glu Glu Ser Leu Glu Glu Leu Pro Glu Thr

55

730 745 760 775
 ACT GCG AAA ACA ACC CCG AGA TTC TTC TTT AAT TTA AGT TCT ATC CCC ACG GCG
 Ser Gly Lys Thr Thr Arg Arg Phe Phe Phe Asn Leu Ser Ser Ile Pro Thr Glu
 5

790 805 820 835
 GAG TTT ATC ACC TCA GCA GAG CTT CAG GTT TTC CGA GAA CAG ATG CAA GAT GCT
 Glu Phe Ile Thr Ser Ala Glu Leu Gln Val Phe Arg Glu Gln MET Gln Asp Ala

10 850 865 880
 TTA GGA AAC AAT AGC AGT TTC CAT CAC CGA ATT AAT ATT TAT GAA ATC ATA AAA
 Leu Gly Asn Asn Ser Ser Phe His His Arg Ile Asn Ile Tyr Glu Ile Ile Lys

15 895 910 925 940
 CCT GCA ACA GCC AAC TCG AAA TTC CCC GTG ACC AGT CTT TTG GAC ACC AGG TTG
 Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Leu

20 955 970 985
 GTG AAT CAG AAT GCA AGC AGG TGG GAA AGT TTT GAT GTC ACC CCC CCT GTG ATG
 Val Asn Gln Asn Ala Ser Arg Trp Glu Ser Phe Asp Val Thr Pro Ala Val MET

25 1000 1015 1030 1045
 CCG TGG ACT GCA CAG GGA CAC CCC AAC CAT GGA TTC GTG GTG GAA GTG GCC CAC
 Arg Trp Thr Ala Gln Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His

30 1060 1075 1090 1105
 TTG GAG GAG AAA CAA GGT GTC TCC AAG AGA CAT GTT AGG ATA ACC AGG TCT TTG
 Leu Glu Glu Lys Gln Gly Val Ser Lys Arg His Val Arg Ile Ser Arg Ser Leu

35 1120 1135 1150
 CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTA GIA ACT TTT GCC
 His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu Val Thr Phe Gly

40 1165 1180 1195 1210
 CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CGT CAA GCC AAA CAC
 His Asp Gly Lys Gly His Pro Leu His Lys Arg Glu Lys Arg Gln Ala Lys His

45 1225 1240 1255
 AAA CAG CGG AAA CGC CCT AAG TCC AGC TGT AAG AGA CAC CCT TTG TAC GTG GAC
 Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp

50 1270 1285 1300 1315
 TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT GTG GCT CCC CGG CGG TAT CAC GCC
 Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala

55 1330 1345 1360 1375
 TTT TAC TGC CAC CGA GAA TGC CCT TTT CCT CTG GCT GAT CTT CTG AAC TCC ACT
 Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr

60 1390 1405 1420
 ATT CCT GCC ATT GTT CAG ACG TTG GTC AAC TCT GTT AAC TCT AAG ATT CCT AAG
 Asn His Ala Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys

1435 1450 1465 1480
 GCA TGC TGT GTC CGG ACA GAA CTC AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG
 Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser MET Leu Tyr Leu Asp Glu

5 1495 1510 1525
 ATG GAA AAG GTT GTA TTA AAG AAC TAT CAG GAC ATG GTT GTG GAG GGT TGT GGG
 Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp MET Val Val Glu Gly Cys Gly

10 1540(396) 1553 1563 1573 1583 1593 1603
 TGT CGC TAGTACAGCA AAATTTAATAA CTTAAATTCAT TATATATATA TATATTTTAG AAAAAAGAAA
 Cys Arg

15 **AAAA**

2. Gène codant pour la BMP-2 humaine comportant la séquence d'acides aminés donnée à la revendication 1.
3. Gène codant pour une protéine montrant des propriétés de la BMP-2 humaine et comprenant une séquence d'ADN :
 - (a) qui diffère d'une séquence d'ADN de la revendication 1 dans la séquence de codons du fait de la dégénérescence du code génétique ;
 - (b) qui s'hybride avec une séquence d'ADN de la revendication 1 ou du paragraphe (a) ci-dessus ; ou
 - 25 (c) représente un fragment, une variation allélique ou autre d'une séquence d'ADN de la revendication 1, que cette variation résulte de changements dans la séquence peptidique ou non.
4. Séquence d'ADN suivant la revendication 3, qui est une séquence d'ADN génomique.
- 30 5. Séquence d'ADN suivant la revendication 3, qui est une séquence d'ADNc.
6. Gène codant pour la BMP-2 bovine comprenant la séquence d'ADN suivante :

35

40

45

50

55

(1) 15 30 45
 GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG
 G H D G K G H P L H R R E K R .

5 60 75 90
 CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG
 Q A K H K Q R K R L K S S C K

10 105 120 135
 AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC
 R H P L Y V D F S D V G W N D

15 150 165 180
 TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG
 W I V A P P G Y H A F Y C H G

20 195 210 225
 GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT
 E C P F P L A D H L N S T N H

25 240 255 270
 GCC ATT CTC CAA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC
 A I V Q T L V N S V N S K I P

30 385 300 315
 AAG GCA TGC TGT GTC CCA ACA GAG CTC AGC GCC ATC TCC ATG CTG
 K A C C V P T E L S A I S M L

35 330 345 360
 TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC
 Y L D E N E K V V L K N Y Q D

40 375 (129) 397 407
 ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAAATA
M V V E G C G C R

45 417 427 437 447 457
 TAAATATATA TATATATATA TTAGAAAAAC AGCAAAAAAA TCAAGTTGAC

50 467 477 487 497 507
 ACTTTAATAT TTCCCATGA AGACTTTATT TATGGATGG AATGGAGAA

517 527 537 547 557
 AAGAAAAACA CAGCTATTTT GAAAACATA TTTATATCTA CCCAAAGAA

567 577 587
 GTTGGGAAAA CAAATTTT AATCAGAGAA TTATT

7. Gène codant pour la BMP-2 bovine contenant la séquence d'acides aminés de la revendication 6.
- 55 8. Gène codant pour une protéine montrant des propriétés de la BMP-2 bovine et comprenant des séquences d'ADN :
- (a) qui diffèrent d'une séquence d'ADN de la revendication 7 dans la séquence des codons du fait de la dégénérescence du code génétique ;

(b) qui s'hybrident avec une séquence d'ADN de la revendication 7 ou du paragraphe (a) ci-dessus ; ou
(c) représentent des fragments, des variations alléliques ou autres d'une séquence d'ADN de la revendication 7, que ces variations résultent de changements dans la séquence peptidique ou non.

35

40

45

50

417 432 447 462
 GGT AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA CGA GCC CGC
 Gly Asn Arg MET Leu MET Val Val Leu Leu Cys Gln Val Leu Leu Gly Gly Ala
 5
 477 492 507
 ACC CAT GCT AGT TTG ATA CCT GAG AGC GGG AAG AAA AAA GTC GGC GAG ATT CAG
 Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Lys Val Ala Glu Ile Gin
 10 522 537 552 567
 GGC CAC CGG CGA CGA CGC CGC TCA GGG CAG AGC CAT GAG CTC CTG CTC CGG GAC TTC
 Gly His Ala Gly Gly Arg Ser Gly Gln Ser His Glu Leu Leu Arg Asp Phe
 15 582 597 612 627
 GAG GCG ACA CTT CTG CAG ATG TTT GGG CTG CGC CGC CGC CGG CAG CCT AGC AAG
 Glu Ala Thr Leu Leu Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys
 20
 642 657 672
 AGT GCC GTC ATT CGG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT GGG GAG
 Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu
 25
 687 702 717 732
 GAG GAG GAA GAG CAG ATC CAC AGC ACT GGT CTT GAG TAT CCT GAG CGC CGG CGC
 Glu Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala
 30 747 762 777
 AGC CGG GCC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC
 Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile
 35 792 807 822 837
 CCA GGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC
 Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile
 40 852 867 882 897
 CCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CTT CGG CTC TTC CGG GAG CAG GTG
 Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val
 45 912 927 942
 GAC CAG GGC OCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT TAT GAG GTT
 Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val
 50 957 972 987 1002
 ATG AAG CCC CCA GCA GAA GTG GTG CCT CGG CAC CTC ATC ACA CGA CTC CTG GAC
 MET Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp
 55 1017 1032 1047
 ACC AGA CTG GTC CAC CGC AAT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCT
 Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro
 60 1052 1077 1092 1107
 CGG GTC CTT CGC TGG ACC CGG GAG AGC CGC CCA AAC TAT CGG CTC CGC ATT GAG
 Ala Val Leu Arg Trp Thr Arg Glu Lys Gln Pro Asn Tyr Gly Leu Ala Ile Glu
 65 1122 1137 1152 1167
 GTG ACT CGC CTC CAT CGG ACT CGG ACC CGC CGG GGC CGG CAT GTC AGG ATT AGC
 Val Thr His Leu His Gln Thr Arg Thr His Gln Gly Gln His Val Arg Ile Ser

1162 1197 1212

CGA TCG TTA CCT CAA GGG AGT GGG AAT TGG GCC CGG CTC CGG CCC CTC CTG GTC
Arg Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu Val

5 1227 1242 1257 1272

ACC TTT GCC CAT GAT GGC CGG GGC CAT GCC TTG ACC CGA CCC CGG AGG CCC AAG
Thr Phe Gly His Asp Gly Arg His Ala Leu Thr Arg Arg Arg Ala Lys

10 1287 1302 1317

CCT AGC CCT AAG CAT CRC TCA CGG CGG GCC AGG AAG AAG AAT AAC TGC CGG
Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg

15 1332 1347 1362 1377

CGC CAC TCG CTC TAT GTG GAC TTC AGC GAT GTG GGC TGG AAT GAC TGG ATT GTG
Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val

20 1392 1407 1422 1437

GCC CCA CCA CGC TAC CGG GGC TTC TAC TGC CAT CGG GAC TGC CCC TTT CCA CTG
Ala Pro Pro Glv Tvr Gln Ala Phe Tvr Cvs His Glv Asn Cvs Pro Phe Pro Leu

25 1452 1467 1482

GCT GAC CAC CTC AAC TCA ACC AAC CAT GCC ATT GTG CAG ACC CTG GTC ATT TCT
Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser

30 1497 1512 1527 1542

GTC AAT TCC AGT ATC CCC AAA GGC TGT TGT GTG CCC ACT GAA CTG AGT CCC ATC
Val Asn Ser Ser Ile Pro Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile

35 1557 1572 1587

TCC ATG CTG TAC CTG GAT TAT GAT AAG GTG GTA CTG AAA AAT TAT CGG GAG
Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu

40 1602 1617 (408) 1636 1646 1656

ATG GTA GTA GAG GGA TGT GGC TGC CGC TGAGATCAGG CAGTCCTGGA CGATAGACAG
Met Val Val Glu Gly Cys Gly Cys Arg

45 1666 1676 1686 1696 1706 1716 1726

ATATAACAC CACACACAC CACACACAC ACCACACAC CACGTCCCCA TCCACCTCAC CACACACTAC

50 1736 1746 1756 1766 1776 1786 1795

ACAGACTGCT TCCCTAACG TGGCTTTTA TTTAAAAAAA AAAAAAAAATGGAAAAA ATGGTTAAC

55 1806 1816 1826 1836 1846 1856 1866

ATTCACCTTG ACCCTTTTA TGACTTTACG TGCAATTGT TTAGCCATTAT TGATCATATP TTTTGACAAA

60 1876 1886 1896 1906 1916 1925 1936

AATTAATTAAT AACACGTTT TAAAGAAA AATTAATTTG AGTCATTTT TTTAAAAAAA AAAAAAAACT

65 1946

CTAGAGTOGA CGGAATTC

- 55 12. Gène codant pour la BMP-4 humaine comportant la séquence d'acides aminés donnée à la revendication 11.
13. Gène codant pour une protéine montrant des propriétés de la BMP-4 et comprenant une séquence d'ADN :

- (a) qui diffère d'une séquence d'ADN de la revendication 11 dans la séquence des codons du fait de la dégénérescence du code génétique ;
 (b) qui s'hybride avec une séquence d'ADN de la revendication 11 ou du paragraphe (a) ci-dessus ; ou
 (c) représente un fragment, une variation allélique ou autre d'une séquence d'ADN de la revendication 11, que cette variation résulte de changements dans la séquence peptidique ou non.
- 5 14. Séquence d'ADN suivant la revendication 13, qui est une séquence d'ADN génomique.
- 10 15. Séquence d'ADN suivant la revendication 13, qui est une séquence d'ADNc.
16. Vecteur contenant le gène ou la séquence d'ADN suivant l'une quelconque des revendications 1 à 15, en association active avec une séquence de contrôle d'expression.
17. Cellule transformée avec un vecteur de la revendication 16.
18. Cellule suivant la revendication 17, qui est une cellule mammifère, une cellule bactérienne, une cellule d'insecte ou une cellule de levure.
19. Cellule suivant la revendication 18, qui est une cellule CHO.
- 20 20. Protéine montrant des propriétés de la BMP-2, qui est codée par un gène ou une séquence d'ADN de l'une quelconque des revendications 1 à 10.
21. Protéine montrant des propriétés de la BMP-2, qui est obtenable par les étapes de culture dans un milieu de culture approprié d'une cellule transformée avec un vecteur d'expression comprenant un gène ou une séquence d'ADN de l'une quelconque des revendications 1 à 10, et de récupération de ladite protéine du milieu de culture précité.
22. Protéine montrant des propriétés de la BMP-4, qui est codée par un gène ou une séquence d'ADN de l'une quelconque des revendications 11 à 15.
- 30 23. Protéine montrant des propriétés de la BMP-4, qui est obtenable par les étapes de culture dans un milieu de culture approprié d'une cellule transformée avec un vecteur d'expression comprenant un gène ou une séquence d'ADN de l'une quelconque des revendications 11 à 15, et de récupération de ladite protéine du milieu de culture précité.
- 35 24. Procédé de production de la protéine suivant l'une ou l'autre des revendications 21 et 23, comprenant les étapes de culture dans un milieu de culture approprié de la cellule de la revendication 17 et d'isolement de ladite protéine du milieu de culture précité.
- 40 25. Composition pharmaceutique comprenant les protéines de l'une quelconque des revendications 20 à 23, individuellement ou en combinaison, et un véhicule pharmaceutiquement acceptable.
26. Composition pharmaceutique suivant la revendication 25, comprenant de plus une matrice pouvant distribuer la composition au site de l'anomalie osseuse ou cartilagineuse et formant une structure pour induire une formation osseuse ou cartilagineuse.
- 45 27. Composition pharmaceutique suivant la revendication 26, dans laquelle ladite matrice comprend de l'hydroxyapatite, du collagène, de l'acide polylactique ou du phosphate tricalcique.
- 50 28. Utilisation d'une protéine suivant l'une quelconque des revendications 20 à 23, individuellement ou en combinaison, pour la préparation d'une composition pharmaceutique pour induire une formation osseuse ou cartilagineuse.

Revendications pour l'Etat contractant suivant : AT

- 55 1. Procédé de préparation d'un gène codant pour la BMP-2 humaine comprenant la séquence d'ADN suivante :

10 20 30 40 50 60 70
 GTCGACTCTA GAGTGTTGTG CAGCAGCTGG CTGGGGACIT CTGAACTTG CAGGGAGAT AACCTGCCA
 5
 80 90 100 110 120 130 140
 CCCACCTTGC CGCGGGTGCC TTGCGGCG AGGAGCGTC TTGCGCTCT CGAGGCGGCA CGGGCGCTCC
 10 150 160 170 180 190 200 210
 ACTCTCGGC CTGCGCGAC ACTGAGACSC TGTGCGAGC GTGAAAAGAG AGACTCGCG AGGGCGCCC
 15 220 230 240 250 260 270 280
 CGGAGAGGA GGAGGCAAAAG AAAAGGAAAG GACATGGGT CCTTGCGCCA GGTGCTTGA CGAGGTTT
 20 290 300 310 320 330 340 350
 TCCATGTTGA CCTCTTTCA ATGGAGCTGT CGCGCGTC TTCTTGAG GACTGGGTC TCCATAGGT
 (1) 370 385 400
 CGCC ATG GTG GGC GGG ACC CGC TGT CTT CTA CGG TTG CTG CTT CGC CGG GTC
 MET Val Ala Gly Thr Arg Cys Leu Leu Ala Leu Ieu Ieu Leu Pro Gln Val
 25 415 430 445
 CTC CTG CGC CGC CGG GCT CGC CTC GTC CGG CGG CGC CGG AGG Arg TTC CGG
 Leu Leu Gly Gly Ala Ala Gly Leu Val Pro Glu Leu Gly Arg Arg Lys Phe Ala
 30 460 475 490 505
 CGG CGG TCG TCG CGC CGC CGC TCA TCC CGG CGC CGC TCT GTC GAG GTC CTG ACC GAG
 Ala Ala Ser Ser Gly Arg Pro Ser Ser Gln Pro Ser Asp Glu Val Leu Ser Glu
 35 520 535 550 565
 TTC GAG TTG CGG CTG CTC AGC ATG TTC CGC CGC CGC AAA CAG AGA CGG ACC CCC ACC
 Phe Glu Leu Arg Leu Leu Ser MET Phe Gly Leu Lys Gln Arg Pro Thr Pro Ser
 40 580 595 610
 ACG GAC CGC CTG CTG CGC CGC TAC ATG CTC GAC CTG TAT CGC AGG CGC TCG CGT
 Arg Asp Ala Val Val Pro Pro Tyr MET Leu Asp Leu Tyr Arg Arg His Ser Gly
 45 625 640 655 670
 CGG CGG CGC TCA CGC CGC CGA GAC CGC CGG TTG GAG AGG CGA CGG ACC CGA CGC
 Gln Pro Gly Ser Pro Ala Pro Asp His Arg Leu Glu Arg Ala Ser Arg Ala
 50 685 700 715
 AAC ACT GTG CGC AGC TTC CTC CGC CTT GAA GAA TCT TTG GAA GAA CTC CGA GAA ACC
 Asn Thr Val Arg Ser Phe His His Glu Glu Ser Leu Glu Glu Leu Pro Glu Thr

50

55

730 745 760 775
 AGT GGG AAA ACA ACC CGG AGA TTC TTC TTT AAT TTA AGT TCT ATC CCC ACC CAG CAG
 Ser Gly Lys Thr Tyr Arg Arg Phe Phe Asn Leu Ser Ser Ile Pro Thr Glu
 5
 790 805 820 835
 GAG TTT ATC ACC TCA GCA GAG CTT CAG GTT TTC CGA GAA CAG ATG CAA GAT GCT
 Glu Phe Ile Thr Ser Ala Glu Leu Gln Val Phe Arg Glu Gln MET Gln Asp Ala
 10 850 865 880
 TTA GCA AAC AAT AGC AGT TTC CAT CAC CGA ATT AAT ATT TAT GAA ATC ATA AAA
 Leu Gly Asn Asn Ser Ser Phe His His Arg Ile Asn Ile Tyr Glu Ile Ile Lys
 15 895 910 925 940
 CCT GCA ACA GCA AAC TCG AAA TTC CCC GTG ACC AGT CTT TTG GAC ACC ACC TTG
 Pro Ala Thr Ala Asn Ser Lys Phe Pro Val Thr Ser Leu Leu Asp Thr Arg Leu
 20 955 970 985
 GTG AAT CAG AAT GCA ACC AGC TCG GAA AGT TTT GAT GTC ACC CCC GCT GTG ATG
 Val Asn Gln Asn Ala Ser Arg Trp Glu Ser Phe Asp Val Thr Pro Ala Val MET
 1000 1015 1030 1045
 CGG TGG ACT GCA CAG GGA CAC GCC AAC CAT GCA TTC GTG GTG GAA GTG GCC CAC
 Arg Trp Thr Ala Gln Gly His Ala Asn His Gly Phe Val Val Glu Val Ala His
 25 1060 1075 1090 1105
 TTG GAG GAG AAA CAA GGT GTC TCC AAG AGA CAT GTT ACG ATA ACC AGG TCT TTG
 Leu Glu Glu Lys Gln Gly Val Ser Lys Arg His Val Arg Ile Ser Arg Ser Leu
 30 1120 1135 1150
 CAC CAA GAT GAA CAC AGC TGG TCA CAG ATA AGG CCA TTG CTA GAA ACT TTT CCC
 His Gln Asp Glu His Ser Trp Ser Gln Ile Arg Pro Leu Leu Val Thr Phe Gly
 35 1165 1180 1195 1210
 CAT GAT GGA AAA GGG CAT CCT CTC CAC AAA AGA GAA AAA CCT CAA GGC AAA CAC
 His Asp Gly Lys Gly His Pro Leu His Lys Arg Glu Lys Arg Gln Ala Lys His
 40 1225 1240 1255
 AAA CAG CGG AAA CGC CTT AAG TCC AGC TGT AAG AGA CAC CCT TTG TAC GTG GAC
 Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg His Pro Leu Tyr Val Asp
 45 1270 1285 1300 1315
 TTC AGT GAC GTG GGG TGG AAT GAC TGG ATT GTG GCT CCC CGG TAT CAC GGC
 Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val Ala Pro Pro Gly Tyr His Ala
 50 1330 1345 1360 1375
 TTT TAC TGC CAC CGA GAA TGC CCT TTT CCT CTG GCT GAT CAT CTG AAC TCC ACT
 Phe Tyr Cys His Gly Glu Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr
 55 1390 1405 1420
 ATG GAT GGC ATT GTT CAG ACG TTG GTC AAC TCT GTT AAC TCT AAG ATT CCT AAC
 Asn His Ala Ile Val Gln Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys

1435 1450 1465 1480
 GCA TGC TGT GTC CGG ACA GAA CTC AGT GCT ATC TCG ATG CTG TAC CTT GAC GAG
 Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile Ser MET Leu Tyr Leu Asp Glu

5 1495 1510 1525
 AAT GAA AAG GTT GTA TTA AAG AAC TAT CAG GAC ATG GTT GTG GAG CGT TGT GGG
 Asn Glu Lys Val Val Leu Lys Asn Tyr Gln Asp MET Val Val Glu Gly Cys Gly

10 1540(396) 1553 1563 1573 1583 1593 1603
 TGT CGC TAGTACAGCA AAATTTAATA CATAAATAATA TATATATATA TATATTTTAG AAAAAAGAAA
 Cys Arg

15 **AAAA ,**

dans lequel ledit procédé comprend les étapes suivantes

- 20 a) la sélection d'une bibliothèque de gènes construite à partir d'ADN ou d'ADNc provenant de U-2 OS avec un fragment de bBMP-2 marqué par hybridation,
 - b) l'isolement des clones positifs, et
 - c) l'isolement des inserts d'ADN de ces clones.
- 25 2. Procédé suivant la revendication 1, dans lequel le gène code pour la BMP-2 humaine ayant la séquence d'acides aminés donnée à la revendication 1.
- 30 3. Procédé de préparation d'un gène codant pour une protéine montrant des propriétés de la BMP-2 humaine et comprenant une séquence d'ADN :
 - a) qui diffère d'une séquence d'ADN de la revendication 1 dans la séquence des codons du fait de la dégénérescence du code génétique ;
 - b) qui s'hybride avec une séquence d'ADN de la revendication 1 ou du paragraphe (a) ci-dessus ; ou
 - c) représente un fragment, une variation allélique ou autre d'une séquence d'ADN de la revendication 1, que cette variation résulte de changements dans la séquence peptidique ou non,
- 35 dans lequel le procédé susdit comprend des techniques standards de biologie moléculaire.
- 40 4. Procédé suivant la revendication 3, dans lequel la séquence d'ADN est une séquence d'ADN génomique.
- 45 5. Procédé suivant la revendication 3, dans lequel la séquence d'ADN est une séquence d'ADNc.
- 50 6. Procédé de préparation d'un gène codant pour la BMP-2 bovine comprenant la séquence d'ADN suivante :

45

50

55

(1) 15 30 45
 GGC CAC GAT GGG AAA GGA CAC CCT CTC CAC AGA AGA GAA AAG CGG
 G H D G K G H P L H R R E K R

5 60 75 90
 CAA GCA AAA CAC AAA CAG CGG AAA CGC CTC AAG TCC AGC TGT AAG
 Q A K H K Q R K R L K S S C K

10 105 120 135
 AGA CAC CCT TTA TAT GTG GAC TTC AGT GAT GTG GGG TGG AAT GAC
 R H P L Y V D F S D V G W N D

15 150 165 180
 TGG ATC GTT GCA CCG CCG GGG TAT CAT GCC TTT TAC TGC CAT GGG
 W I V A P P G Y H A F Y C H G

20 195 210 225
 GAG TGC CCT TTT CCC CTG GCC GAT CAC CTT AAC TCC ACG AAT CAT
 E C P F P L A D H L N S T N H

25 240 255 270
 GGC ATT CTC CAA ACT CTG GTC AAC TCA GTT AAC TCT AAG ATT CCC
 A I V Q T L V N S V N S K I P

30 365 380 315
 AAG GCA TGC TGT GTC CCA ACA GAG CTC AGC GCC ATC TCC ATG CTG
 K A C C V P T E L S A I S M L

35 330 345 360
 TAC CTT GAT GAG AAT GAG AAG GTG GTA TTA AAG AAC TAT CAG GAC
 Y L D E N E K V V L K N Y O D

40 375 (129) 397 407
 ATG GTT GTC GAG GGT TGT GGG TGT CGT TAGCACAGCA AAATAAATAA
 M V V E G C G C R

45 417 427 437 447 457
 TAAATATATA TATATATATA TTAGAAAAAC AGCAAAAAAA TCAAGTTGAC

50 467 477 487 497 507
 ACTTTAATAT TTCCCCATGA AGACTTTATT TATGGAAATGG AATGGAGAAA

55 517 527 537 547 557
 AAGAAAAAAC AAGCTATTT GAAACTATA TTTATATCTA CCGAAAAAGAA

567 577 587
 GTTGGGAAAA CAAATATTTT AATCAGAGAA TTATT,

dans lequel ledit procédé comprend les étapes suivantes :

- a) la sélection d'une bibliothèque de gènes construite à partir d'ADN ou d'ADNc provenant de foie bovin avec une sonde marquée conçue sur la base de la séquence d'acides aminés d'un fragment de bBMP-2,
- 55 b) l'isolement des clones positifs, et
- c) l'isolement des inserts d'ADN de ces clones.

7. Procédé suivant la revendication 6, dans lequel le gène code pour de la BMP-2 bovine ayant la séquence d'acides

aminés de la revendication 6.

8. Procédé de préparation d'un gène codant pour une protéine montrant des propriétés de la BMP-2 bovine et comprenant des séquences d'ADN :

5

- a) qui diffèrent d'une séquence d'ADN de la revendication 7 dans la séquence des codons du fait de la dégénérescence du code génétique ;
- b) qui s'hybrident avec une séquence d'ADN de la revendication 7 ou du paragraphe a) ci-dessus ; ou
- c) représentent des fragments, des variations alléliques ou autres d'une séquence d'ADN de la revendication 10 7, que ces variations résultent de changements dans la séquence peptidique ou non,

dans lequel le procédé précité comprend des techniques standards de biologie moléculaire.

9. Procédé suivant la revendication 8, dans lequel la séquence d'ADN est une séquence d'ADN génomique.

15

10. Procédé suivant la revendication 8, dans lequel la séquence d'ADN est une séquence d'ADNc.

11. Procédé de préparation d'un gène codant pour la BMP-4 humaine comprenant la séquence d'ADN suivante :

20

25

30

35

40

45

50

55

10 20 30 40 50 60 70

CCTCTAGGGG CAGAGGAGA GGGAGGGG GAGGGAGGC GGAGGGGGC CGCGAGCTA GGTGAGTG

5 80 90 100 110 120 130 140

GCATGGAGC TGAGGGAGC GAGCTAGA CGGGCTGCT GCTGGGCTG AGTATCTAGC TTGTCATCCC

10 150 160 170 180 190 200 210

GATGGGATC CGCTGGAGC TATCTAGC CTGAGGGGC ACAGTOGGG GGGCTAGCC AGGTTCACG

15 220 230 240 250 260 270 280

CAACGGTTCA GGGGGGCGA CGGGCTCTG CTGGGGAGCC CGCTACTGCA GGGACCTTG GAGCTTCC

290 300 310 320 330 340 350

GTAGTGCCAT CGGGGGCAC GCAGCTGCTG AGCTTOCCG AGCCCTTCCA GCAAGTTTG TCAAGTTGG

20 360 370 380 390 400 (1)

CCTCTAGAA TCATGGACTG TTTTATATG CCTTGTTTC TGTCAGAGCA CC ATG ATT CCT
MET Ile Pro ..

25 417 432 447 462

GGT AAC CGA ATG CTG ATG GTC GTT TTA TTA TGC CAA GTC CTG CTA CGA CCC CGG
Gly Asn Arg MET Leu MET Val Val Leu Leu Cys Gln Val Leu Leu Gly Gly Ala

30 477 492 507

AGC CAT GCT ATG TTG ATA CCT GAG ACG CGG AAG AAA AAA GTC CCC GAG ATT CAG
Ser His Ala Ser Leu Ile Pro Glu Thr Gly Lys Lys Val Ala Glu Ile Gln

35 522 537 552 567

GGC CAC GCG GGA CGA CGC CGC TCA GGG CAG ACG CAT GAG CTC CTG CGG GAC TTC
Gly His Ala Gly Gly Arg Arg Ser Gly Gln Ser His Glu Leu Leu Arg Asp Phe

40 582 597 612 627

GAG GCG ACA CTT CTG CAG ATG TTT GGG CTG CGC CGC CGG CAG CCT AGC AAG
Glu Ala Thr Leu Leu Gln MET Phe Gly Leu Arg Arg Pro Gln Pro Ser Lys

45 642 657 672

AGT GCG GTC ATT CGG GAC TAC ATG CGG GAT CTT TAC CGG CTT CAG TCT GGG GAG
Ser Ala Val Ile Pro Asp Tyr MET Arg Asp Leu Tyr Arg Leu Gln Ser Gly Glu

50 687 702 717 732

GAG GAG GAA GAG CGG ATC CAC ACG ACT GGT CTT GAG TAT CCT GAG CGC CGG GCG
Glu Glu Glu Glu Gln Ile His Ser Thr Gly Leu Glu Tyr Pro Glu Arg Pro Ala

50

55

747 762 777

AGC CGG GCC AAC ACC GTG AGG AGC TTC CAC CAC GAA GAA CAT CTG GAG AAC ATC
Ser Arg Ala Asn Thr Val Arg Ser Phe His His Glu Glu His Leu Glu Asn Ile

5 792 807 822 837

CCA CGG ACC AGT GAA AAC TCT GCT TTT CGT TTC CTC TTT AAC CTC AGC AGC ATC
Pro Gly Thr Ser Glu Asn Ser Ala Phe Arg Phe Leu Phe Asn Leu Ser Ser Ile

10 852 867 882 897

CCT GAG AAC GAG GTG ATC TCC TCT GCA GAG CTC CGG CTC TTC CGG GAG CAG GTG
Pro Glu Asn Glu Val Ile Ser Ser Ala Glu Leu Arg Leu Phe Arg Glu Gln Val

15 912 927 942

GAC CAG GGC CCT GAT TGG GAA AGG GGC TTC CAC CGT ATA AAC ATT TAT GAG GTT
Asp Gln Gly Pro Asp Trp Glu Arg Gly Phe His Arg Ile Asn Ile Tyr Glu Val

20 957 972 987 1002

ATG AAG CCC CCA GCA GAA GTG GTG CCT CGG CAC CTC ATC ACA CGA CTA CTG GAC
Met Lys Pro Pro Ala Glu Val Val Pro Gly His Leu Ile Thr Arg Leu Leu Asp

25 1017 1032 1047

ACG AGA CTG GTC CTC CTC AAC ATT GTG ACA CGG TGG GAA ACT TTT GAT GTG AGC CCT
Thr Arg Leu Val His His Asn Val Thr Arg Trp Glu Thr Phe Asp Val Ser Pro

30 1052 1077 1092 1107

CGG GTC CCT CGC TGG ACC CGG GAG AAG CAG CCA AAC TAT GGG CTC GGC ATT GAG
Ala Val Leu Arg Trp Thr Arg Glu Lys Gln Pro Asn Tyr Gly Leu Ala Ile Glu

35 1122 1137 1152 1167

GTG ACT CAC CTC CAT CGG ACT CGG ACC CAC CAG GGC CAG CAT GTC AGG ATT AGC
Val Thr His Leu His Gln Thr Arg Trp His Gln Gly Gln His Val Arg Ile Ser

40 1182 1197 1212

CGA TCG TTA CCT CPA CGG AGT GGG ATT TGG GCG CTC CGG CGC CTC CTG GTC
Arg Ser Leu Pro Gln Gly Ser Gly Asn Trp Ala Gln Leu Arg Pro Leu Leu Val

45 1227 1242 1257 1272

ACC TTT GGC CAT GAT CGG CGG CGC CAT GCG TTG ACC CGA CGC CGG AGG GGC AAG
Thr Phe Gly His Asp Gly Arg Gly His Ala Leu Thr Arg Arg Arg Arg Ala Lys

50 1287 1302 1317

CGT AGC CCT AAG CAT CAC TCA CAG CGG GGC AGG AAG AAG ATT AAG AAC TGC CGG
Arg Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys Arg

55 1332 1347 1362 1377

CGC CAC TCG TAT GTG GAC TTC ACC GAT GTG GGC TGG ATT GAC TGG ATT GTG
Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile Val

59 1392 1407 1422 1437

GCG CCA CCA CGC TAC CAG GGC TTC TAC TCC CTC CGG GAC TGC CGC CCC TTT CCA CTG
Ala Pro Pro Glv Tyr Gln Ala Phe Tyr Cys His Glv Asp Cys Pro Phe Pro Leu

65 1452 1467 1482

GCT GAC CAC CTC AAC TCA ACC AAC CAT GCG ATT GTG CAG ACC CTC GTC ATT TCT
Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln Thr Leu Val Asn Ser

1497 1512 1527 1542
 GTC AAT TCC AGT ATC CCC AAA GGC TGT TGT GTG CCC ACT GAA CTG AGT GCC ATC
 5 Val Asn Ser Ser Ile Pro Lys Ala Cys Cys Val Pro Thr Glu Leu Ser Ala Ile

 1557 1572 1587
 TCC ATG CTG TAC CTG GAT GAG TAT GAT AAG GTG GTA CTG AAA ATN TAT CAG GAG
 10 Ser MET Leu Tyr Leu Asp Glu Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu

 1602 1617 (408) 1636 1646 1656
 ATG GIA GIA GAG GGA TGT GGG TGC CGC TGAGATCAGG CAGTCTTGA GGATAGACAG
 MET Val Val Glu Gly Cys Gly Cys Arg

 1666 1676 1686 1696 1706 1716 1726
 ATATACACAC CACACACACA CACACACAC ACCACACACA CAOGTCCCCA TOCACTCACCC CACACACTAC

 1736 1746 1756 1766 1776 1786 1796
 20 ACAGACTGCT TCCCTATAGC TGGACTTTA TTAAAAAAA AAAAAAAA ATGGAAAAAA ATCCCTAAAC :

 1806 1816 1826 1836 1846 1856 1866
 ATTCAACCTTG ACCTTATTTC TGACCTTACG TGCAATTGTT TTGACCATAT TGATCAATAA TTTGACAAA :

 1876 1886 1896 1906 1916 1926 1936
 25 ATATTTTAT AACCTGGTT TAAAGAAA AAATAAATTG AGTCATTATT TTAAAAAAA AAAAAAAACT

 1946
 30 CTAGAGCTGA CGGAATTC ,

dans lequel le procédé précité comprend les étapes suivantes :

- 35 a) la sélection d'une bibliothèque de gènes construite à partir d'ADN ou d'ADNc provenant d'U-2 OS avec un fragment bbMP-2 marqué par hybridation,
 b) l'isolement des clones positifs, et
 c) l'isolement des inserts d'ADN de ces clones.

 40 12. Procédé suivant la revendication 11, dans lequel le gène code pour la BMP-4 humaine ayant la séquence d'acides aminés donnée à la revendication 11.

 13. Procédé de préparation d'un gène codant pour une protéine montrant des propriétés de la BMP-4 et comprenant une séquence d'ADN :

 45 a) qui diffère d'une séquence d'ADN de la revendication 11 dans la séquence des codons du fait de la dégénérescence du code génétique ;
 b) qui s'hybride avec une séquence d'ADN de la revendication 11 ou du paragraphe a) ci-dessus ; ou
 c) représente un fragment, une variation allélique ou autre d'une séquence d'ADN de la revendication 11, que cette variation résulte de changements dans la séquence peptidique ou non,

dans lequel le procédé précité comprend des techniques standards de biologie moléculaire.

- 50 14. Procédé suivant la revendication 13, dans lequel la séquence d'ADN est une séquence d'ADN génomique.

 15. Procédé suivant la revendication 13, dans lequel la séquence d'ADN est une séquence d'ADNc.

 16. Vecteur contenant le gène ou la séquence d'ADN préparé suivant l'une quelconque des revendications 1 à 15, en

association active avec une séquence de contrôle d'expression.

17. Cellule transformée avec un vecteur de la revendication 16.
- 5 18. Cellule suivant la revendication 17, qui est une cellule mammifère, une cellule bactérienne, une cellule d'insecte ou une cellule de levure.
19. Cellule suivant la revendication 18, qui est une cellule CHO.
- 10 20. Procédé de préparation d'une protéine montrant des propriétés de la BMP-2, dans lequel ledit procédé comprend les étapes de culture dans un milieu de culture approprié d'une cellule transformée avec un vecteur d'expression comprenant un gène ou une séquence d'ADN préparé suivant l'une quelconque des revendications 1 à 10 et de récupération de ladite protéine du milieu de culture précité.
- 15 21. Procédé de préparation d'une protéine montrant des propriétés de la BMP-4, dans lequel ledit procédé comprend les étapes de culture dans un milieu de culture approprié d'une cellule transformée avec un vecteur d'expression comprenant un gène ou une séquence d'ADN préparé suivant l'une quelconque des revendications 11 à 15 et de récupération de ladite protéine du milieu de culture précité.
- 20 22. Procédé de production d'une protéine montrant des propriétés de la BMP-2 ou BMP-4, comprenant les étapes de culture dans un milieu de culture approprié de la cellule de la revendication 17 et d'isolement de ladite protéine du milieu de culture précité.
- 25 23. Procédé de préparation d'une composition pharmaceutique comprenant la combinaison des protéines préparées suivant l'une quelconque des revendications 20 à 22, individuellement ou en combinaison avec un véhicule pharmaceutiquement acceptable.
- 30 24. Procédé suivant la revendication 23, dans lequel la composition pharmaceutique susdite comprend de plus une matrice pouvant distribuer la composition au site de l'anomalie osseuse ou cartilagineuse et constituer une structure pour induire une formation osseuse ou cartilagineuse.
- 25 25. Procédé suivant la revendication 24, dans lequel la matrice comprend de l'hydroxyapatite, du collagène, de l'acide polylactique ou du phosphate tricalcique.
- 35 26. Utilisation d'une protéine préparée suivant l'une quelconque des revendications 20 à 22, individuellement ou en combinaison, pour la préparation d'une composition pharmaceutique pour induire une formation osseuse ou cartilagineuse.

40

45

50

55

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.